US8455640B2 - Process for statins and its pharmaceutically acceptable salts thereof - Google Patents

Process for statins and its pharmaceutically acceptable salts thereof Download PDF

Info

Publication number
US8455640B2
US8455640B2 US12/226,932 US22693207A US8455640B2 US 8455640 B2 US8455640 B2 US 8455640B2 US 22693207 A US22693207 A US 22693207A US 8455640 B2 US8455640 B2 US 8455640B2
Authority
US
United States
Prior art keywords
compound
formula
amine
reaction mixture
alkali
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US12/226,932
Other versions
US20090275752A1 (en
Inventor
Manne Satyanarayana Reddy
Srinivasan Thirumalai Rajan
Maramreddy Sahadeva Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSN Laboratories Pvt Ltd
Original Assignee
MSN Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSN Laboratories Pvt Ltd filed Critical MSN Laboratories Pvt Ltd
Assigned to MSN LABORATORIES LIMITED reassignment MSN LABORATORIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RAJAN, SRINIVASAN THIRUMALAI, REDDY, MANNE SATYANARAYANA, REDDY, MARAMREDDY SAHADEVA
Publication of US20090275752A1 publication Critical patent/US20090275752A1/en
Application granted granted Critical
Publication of US8455640B2 publication Critical patent/US8455640B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/283—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/29—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by the general formula-1
  • R is a hydrophobic anchor or residue of an HMG CoA reductase inhibitor and may for example be
  • M is H, Na + , K + , Mg +2 , Ca +2
  • R is H, Na + , K + , Mg +2 , Ca +2
  • the present invention also relates to a novel process for the preparation of olefinic chiral dihydroxy acid and its pharmaceutically acceptable salts HMG CoA reductase inhibitors of general formula-2.
  • R 1 is a hydrophobic anchor or residue of an HMG CoA reductase inhibitor and may for example be
  • the compounds of the present invention inhibit the HMG-CoA reductase, which plays a main role in the synthesis of cholesterol, and subsequently they suppress the biosynthesis of cholesterol. Therefore, they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.
  • the present invention relates to one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by the general formula-1.
  • M is H, Na + , K + , Mg +2 , Ca +2 and R is defined as above.
  • the present invention also relates to a novel process for the preparation of olefinic chiral dihydroxy acid and its pharmaceutically acceptable salts HMG CoA Reductase inhibitors of general formula-2
  • M is H, Na + , K + , Mg +2 , Ca +2 , R 1 is defined as above.
  • the present invention is directed to the synthesis of chiral dihydroxy acid HMG CoA reductase inhibitors (statins) of general formula-1 and formula-2, preferably via sulfide, sulfoxide and sulfone intermediates which is used in preparing a dihydroxy acid HMG CoA reductase inhibitor or lactone thereof.
  • statins chiral dihydroxy acid HMG CoA reductase inhibitors
  • In one aspect of the present invention is to provide one-pot synthesis for the preparation of statin compounds of general formula-1.
  • a Julia-Modified olefination reaction is employed wherein the sulfone intermediate is reacted with carboxylaldehyde to form the desired olefin which is to be isolated in high yield and optical purity which may be converted to the final HMG CoA reductase inhibitor of general formula-2.
  • Rosuvastatin and process for its preparation is disclosed in U.S. Pat. No. 5,260,440 incorporated herein by reference.
  • the process disclosed therein involves four distinct chemical steps and the generation of the phosphorane side chain requires expensive reagents and the process is both uneconomical and time consuming, and statin compounds preparation through wittig reaction leads to the formation of ‘Z’ isomer approximately around 20% as well as poor solubility of calcium salt of rosuvastatin has been observed in an aqueous methanol with this process, which is due to the formation of sodium chloride byproducts. This is a major drawback in the synthesis of calcium salt of rosuvastatin, hence is not suitable for commercial production.
  • Atorvastatin calcium and process for its preparation is disclosed in U.S. Pat. No. 5,273,995 incorporated herein by reference, discloses the enationmer having the R form of the ring-opened acid of trans-5-(4-fluorophenyl)-2-(1-methylethyl)-N-4-diphenyl-1-[(2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide.
  • Fluvastatin sodium and process for its preparation is disclosed in U.S. Pat. No. 4,739,073 incorporated herein by reference, discloses fluvastatin as a racemate and its pharmaceutically acceptable salts especially sodium salt.
  • This patent also discloses process for the preparation of fluvastatin, which involves treating (E)-3-[3′-(4′fluorophenyl)-1′-(1′′-methylethyl)indol-2-yl)-2-propenal with methyl acetoacetate in presence of a strong base like n-butyl lithium and sodium hydride in tetrahydrofuran to get Methyl-( ⁇ )-(E)-7-[3′-(4′′-fluorophenyl)-1′-(1′′-methylethyl)-indol-2′-yl]-5-hydroxiy-3-oxo-hept-6-enoate which is further reacted with triethyl borane, tetrahydro
  • statins which improves the economics by employing less expensive reagents and is more productive compare to the known processes.
  • the present invention provides a novel and advantageous process for the preparation of calcium salt of statins which solves solubility problem of the compound in an aqueous methanol and gives free flow solid of calcium salt.
  • the present invention uses calcium acetate instead of calcium chloride so the byproduct is sodium acetate, which is highly soluble in water. So the obtained compound is freely soluble in methanol.
  • the present invention provides a process which involves less number of steps, without isolation of intermediate, eco-friendly, easy to scale-up and commercially viable for the preparation of statins and its pharmaceutically acceptable salts thereof.
  • a process is provided for preparing chiral dihydroxy acid HMG CoA reductase inhibitors which are useful as anti-cholesterol agents as described hereinafter.
  • the present invention provides a novel process for the preparation of statins and its pharmaceutically acceptable salts compound of general formula-1 and general formula-2
  • M is H, Na + , K + , Mg +2 , Ca +2 and R, R 1 is defined as above.
  • the first aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts represented by general formula-1, which comprises of the following steps
  • the second aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts represented by general formula-1, which comprises of the following steps
  • the third aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts represented by general formula-1, which comprises of the following steps
  • the fourth aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts represented by general formula-1, which comprises of the following steps
  • the fifth aspect of the present invention is to provide a novel process for the preparation of olefin dihydroxy compound of general formula-2 via a Julia-Modified olefination, which comprises of the following steps
  • the saturated derivative of lactone compound of formula-23 may be obtained by catalytic (Pd/C, Pt/C, Pd(OH) 2 ) hydrogenation of compound of formula-23 to compound of formula-24.
  • Lactone compounds of formula-23 and formula-24 may be converted to the corresponding diol compounds by saponification of formula-23 and formula-24 with aqueous base to form corresponding alkali salt compounds of formula-25 and formula-26
  • the sixth aspect of the present invention is to provide a novel process for the preparation of olefin dihydroxy compound of general formula-2 is provided via a Julia-Modified olefination, which comprises of the following steps
  • the seventh aspect of the present invention is to provide a novel process for preparing a novel sulfone and sulfoxide compounds having general Formula-13 and general formula-17, which comprises of the following steps
  • the eighth aspect of the present invention is to provide a novel process for the preparation of calcium salt of statins compounds of general formaula-1 and compound of general formula-2, which comprises of the following steps.
  • M is Calcium and R 1 is defined as above
  • R 1 is as defined above and is linked to sulphur atom with a methylene group and R 2 is as defined above.
  • R 1 is as defined above which is linked to sulphur atom with a methylene group (—CH 2 —) and R 2 is as defined above.
  • R 1 is as defined above which is linked to sulphur atom with a methylene group (—CH 2 —) and R 2 is as defined above.
  • FIG. 1 Illustrates the powder X-ray diffraction pattern of rosuvastatin tertiarybutyl amine
  • FIG. 2 Illustrates the powder X-ray diffraction pattern of amorphous rosuvastatin calcium.
  • novel process is provided for the preparation of chiral dihydroxy acid HMG CoA reductase inhibitors which are useful as anti-cholesterol agents as described hereinafter.
  • the present invention provides a novel process for the preparation of statins and its pharmaceutically acceptable salts compounds of general formula-1 and general formula-2,
  • R is a hydrophobic anchor or residue of an HMG CoA reductase inhibitor and may for example be
  • R 1 is a hydrophobic anchor or residue of an HMG CoA reductase inhibitor and may for example be
  • the first aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by the general formula-1,
  • M is H, Na + , K + , Mg +2 , Ca +2 and R is defined as above Which comprises of the following steps
  • the second aspect of the present invention is to provide a one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by general formula-1
  • M is H, Na + , K + , Mg +2 , Ca +2 and R is defined as above Which comprises of the following steps
  • the third aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by general formula-1
  • R is defined as above and M is H, Na + ,K + ,Mg + ,Ca +2 Which comprises of the following steps
  • the fourth aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by general formula-1,
  • M is H, Na + ,K + ,Mg +2 ,Ca +2 and R is defined as above which comprises of the following steps
  • the fifth aspect of the present invention is to provide a novel process for the preparation of olefinic dihydroxy compound of general formula-2 via a Julia-Modified olefination, which comprises of the following steps
  • the sixth aspect of the present invention is to provide a novel process for the preparation of olefin dihydroxy compound of formula-2 via a Julia-Modified olefination, which comprises of the following steps,
  • the seventh aspect of the present invention is to provide a process for the preparation of a novel sulfone compound of general formula-13 and sulfoxide derivative compound of general formula-17,
  • R 1 is defined as above which is linked to sulphur atom with a methylene group (—CH 2 —) and R 2 is defined as above, which comprises of the following steps
  • the Eighth aspect of the present invention is to provide a novel, process for the preparation of calcium salt compound of general formula-1 and general formula-2,
  • M is Calcium and R 1 is defined as above. Which comprises of the following steps
  • a preferred one-pot synthesis is provided for the preparation of rosuvastatin calcium salt compound of formula-1A, which comprises of the following steps
  • a preferred one-pot synthesis is provided for the preparation of rosuvastatin calcium salt compound of formula-1A, which comprises of the following steps
  • a preferred one-pot synthesis is provided for the preparation of rosuvastatin calcium salt compound of formula-1A
  • a preferred one-pot synthesis is provided for the preparation of rosuvastatin calcium salt compound of formula-1A
  • the one-pot synthesis for the preparation of rosuvastatin calcium compound of formula-1A comprises of the following steps
  • the starting material compounds of general formula-13 can be prepared as per the prior art processes, Ref: U.S. Pat. No. 6,627,636; U.S. Pat. No. 5,763,675 (Pitavastatin); U.S. Pat. No. 5,354,772; U.S. Pat. No. 4,739,073 (Fluvastatin); WO 03/097614; US2004/0176401 and WO03/006439.
  • the starting material aldehyde compound of Formula-13 can be prepared as per the prior art processes, Ref: WO/49014; U.S. Pat. No. 6,844,437; US 20040049036 and in US 2006/0004200 and Tetrahedron Letters, Vol. 31, No. 18, pp 2545-2548, 1990
  • the process of the present invention may be employed to prepare pravastatin, atorvastatin, cerivastatin, fluvastatin, rosuvastatin, nisvastatin (pitavastatin), simvastatin, lovastatin and other dihydroxy acid or lactone HMG CoA reductase inhibitors.
  • M is H, Na + ,K + ,Mg +2 ,Ca +2 and R 1 ,R 2 and R 10 is defined as above denotes single or double bond
  • a solution of 10 grams of sulfide compound of formula-20a prepared as per the example 1 and 100 ml of acetone is cooled to 0-5° C. under nitrogen atmosphere. Added 2.9 grams of potassium carbonate to the above solution then added 3.0 ml of dimethylsulfate to the above reaction mixture and stirred for 4 hours at 0-5° C. Quenched the reaction mixture with chilled water and filtered the precipitated compound. Dried the compound at 50-55° C. for 3 hours.
  • TSA tertiarybutyl amine
  • D (v, 0.1) is 4.72 ⁇ m; D (v, 0.5) is 40.76 ⁇ m; D (v, 0.9) is 168.32 ⁇ m.
  • a mixture of 23.1 Kgs. compound of formula-3A and 90 liters of dimethylsulfoxide and 48 Kgs. of potassium carbonate is heated to 70-75° C.
  • a solution of 12.5 Kgs of rosuvastatin tertiarybutyl amine compound of Formula-5A and 63 liters of water is cooled to 25-30° C.
  • aqueous sodium hydroxide solution (0.9 Kgs. in 11 liters of water) to the reaction mixture. Stirred the reaction mixture for 1 hour. Adjusted the pH of the reaction mixture to 9.1 by extracting the reaction mixture thrice with tertiary butyl acetate.
  • a mixture of 23.1 Kgs. compound of formula-3A and 90 liters of dimethylsulfoxide and 48 Kgs. of potassium carbonate is heated to 70-75° C.
  • a mixture of 0.77 grams of compound of Formula-3A, 10 ml of dimethylsulfoxide and 1.6 grams of potassium carbonate is heated to 70-75° C.
  • a solution of 15 grams of Rosuvastatin tertiarybutyl amine salt compound of formula-5A and 75 ml of water is cooled to 25-30° C. Added 8.5 ml of 10% sodium hydroxide solution. Stirred for 1 hour. Adjusted the pH of the reaction mixture to 9.1 by extracting the reaction mixture thrice with tertiary butyl acetate. Added the aqueous phase of the reaction mixture to a solution of 2.55 grams of calcium chloride and 15 ml of water at 35 to 45° C. Filtered off the precipitated compound. Dried the compound at 40-45° C.
  • a mixture of 77 grams of sulfone compound of formula-3A, 300 ml of dimethyl sulfoxide and 160 grams of potassium carbonate is heated to 70-75° C.
  • D (v, 0.1) is 4.9 ⁇ m; D(v, 0.5) is 45.86 ⁇ m; D(v, 0.9) is 180.59 ⁇ m.
  • D (v, 0.1) is 2.46 ⁇ m; D(v, 0.5) is 12.85 ⁇ m; D(v, 0.9) is 46.43 ⁇ m.
  • D (v, 0.1) is 4.78 ⁇ m; D(v, 0.5) is 42.32 ⁇ m; D(v, 0.9) is 175.32 ⁇ m.
  • D (v, 0.1) is 2.53 ⁇ m; D(v, 0.5) is 10.54 ⁇ m; D(v, 0.9) is 34.14 ⁇ m.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Novel process for statins and its pharmaceutically acceptable salts thereof represented by general formula (I).
Figure US08455640-20130604-C00001

Description

RELATED APPLICATIONS
This application is the U.S. National Stage of International Application No. PCT/IN2007/000172, filed Apr. 30, 2007, published in English, and claims priority under 35 U.S.C. §119 or 365 to Indian Application No. 805/CHE/2006, filed May 3, 2006 and to Indian Application No. 606/CHE/2007 filed Mar. 26, 2007, all of which are incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates to one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by the general formula-1
Figure US08455640-20130604-C00002
Wherein R is a hydrophobic anchor or residue of an HMG CoA reductase inhibitor and may for example be
Figure US08455640-20130604-C00003
Wherein M is H, Na+, K+, Mg+2, Ca+2
Herein after the above compounds of formula A, B and C are referred as ‘R’.
The present invention also relates to a novel process for the preparation of olefinic chiral dihydroxy acid and its pharmaceutically acceptable salts HMG CoA reductase inhibitors of general formula-2.
Figure US08455640-20130604-C00004
Wherein R1 is a hydrophobic anchor or residue of an HMG CoA reductase inhibitor and may for example be
Figure US08455640-20130604-C00005
Figure US08455640-20130604-C00006
wherein
Figure US08455640-20130604-P00001
denotes single or double bond and M is H, Na+, K+, Mg+2, Ca+2
Herein after the above compounds of formula (a), (b), (c), (d), (e), (f), (g) and (h) are referred as ‘R1’
The compounds of the present invention inhibit the HMG-CoA reductase, which plays a main role in the synthesis of cholesterol, and subsequently they suppress the biosynthesis of cholesterol. Therefore, they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.
SUMMARY OF THE INVENTION
The present invention relates to one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by the general formula-1.
Figure US08455640-20130604-C00007
Wherein M is H, Na+, K+, Mg+2, Ca+2 and R is defined as above.
The present invention also relates to a novel process for the preparation of olefinic chiral dihydroxy acid and its pharmaceutically acceptable salts HMG CoA Reductase inhibitors of general formula-2
Figure US08455640-20130604-C00008
wherein
Figure US08455640-20130604-P00002
denotes single or double bond and M is H, Na+, K+, Mg+2, Ca+2, R1 is defined as above.
The present invention is directed to the synthesis of chiral dihydroxy acid HMG CoA reductase inhibitors (statins) of general formula-1 and formula-2, preferably via sulfide, sulfoxide and sulfone intermediates which is used in preparing a dihydroxy acid HMG CoA reductase inhibitor or lactone thereof.
In one aspect of the present invention is to provide one-pot synthesis for the preparation of statin compounds of general formula-1.
In another aspect of the process of the invention, a Julia-Modified olefination reaction is employed wherein the sulfone intermediate is reacted with carboxylaldehyde to form the desired olefin which is to be isolated in high yield and optical purity which may be converted to the final HMG CoA reductase inhibitor of general formula-2.
BACKGROUND OF THE INVENTION
Rosuvastatin and process for its preparation is disclosed in U.S. Pat. No. 5,260,440 incorporated herein by reference. The process disclosed therein involves four distinct chemical steps and the generation of the phosphorane side chain requires expensive reagents and the process is both uneconomical and time consuming, and statin compounds preparation through wittig reaction leads to the formation of ‘Z’ isomer approximately around 20% as well as poor solubility of calcium salt of rosuvastatin has been observed in an aqueous methanol with this process, which is due to the formation of sodium chloride byproducts. This is a major drawback in the synthesis of calcium salt of rosuvastatin, hence is not suitable for commercial production.
Atorvastatin calcium and process for its preparation is disclosed in U.S. Pat. No. 5,273,995 incorporated herein by reference, discloses the enationmer having the R form of the ring-opened acid of trans-5-(4-fluorophenyl)-2-(1-methylethyl)-N-4-diphenyl-1-[(2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide. i.e., [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamineo) carbonyl]-1H-pyrrole-1-heptanoic acid.
Fluvastatin sodium and process for its preparation is disclosed in U.S. Pat. No. 4,739,073 incorporated herein by reference, discloses fluvastatin as a racemate and its pharmaceutically acceptable salts especially sodium salt. This patent also discloses process for the preparation of fluvastatin, which involves treating (E)-3-[3′-(4′fluorophenyl)-1′-(1″-methylethyl)indol-2-yl)-2-propenal with methyl acetoacetate in presence of a strong base like n-butyl lithium and sodium hydride in tetrahydrofuran to get Methyl-(±)-(E)-7-[3′-(4″-fluorophenyl)-1′-(1″-methylethyl)-indol-2′-yl]-5-hydroxiy-3-oxo-hept-6-enoate which is further reacted with triethyl borane, tetrahydrofuran and sodium borohydride to get (±)-Erythro-7-(4″-Fluorophenyl)-1′-(1″-methylethyl)-indol-2′-yl]-3,5-dihydroxyhept-6-enoate, methyl ester followed by treated with anhydrous methanol to get the methyl(±)-erythro-(E)-3,5-dihydroxy-7-[3′-(4″-fluorophenyl)-1′-(1″-methylethyl)indol-2′-yl]hept-6-enoate(diol ester) which is purified by the column chromatography. The diol ester compound is hydrolysed with aqueous sodium hydroxide solution to get the fluvastatin sodium.
Pitavastatin and process for its preparation is disclosed in EP patent 304063 and EP 1099694 and in the publication by N. Miyachi et al. in Tetrahedron Letters 1993, Vol. 34, page no. 8267-8270 and by K. Takahashi et al. in Bull. Chem. Soc. Jpn. 1995, Vol. 68, 2649-2656. These publications describe the synthesis of Pitavastatin in great detail.
Our earlier Indian patent application 782/CHE/2005 published in Indian patent Journal on 18th Aug. 2006 incorporated herein by reference, discloses a novel process for the preparation of rosuvastatin calcium. The said patent also discloses following organic amine salt of rosuvastatin, cyclic amines such as cyclopropyl amine, cyclo pentyl amine, cyclo hexyl amine, dicyclohexyl amine, pyrrolidine or morpholine or alkylamines such as isopropyl amine, diisopropyl amine, phenyl propyl amine, tertiary butyl amine and its analogues. It further discloses the purification of organic amine salts in acetone, acetonitrile or mixture of acetonitrile and isopropyl alcohol.
Tetrahedron Letters, Vol. 31, No. 18, pp 2545-2548, 1990 incorporated herein by reference, discloses stereo selective synthesis of HMG-COA reductase inhibitors through lactone intermediate i.e., corresponding protected ester compound on reaction with trifluoroacetic acid. The said journal discloses the pyridine derivative compound as HMG-COA reductase inhibitor and disclosed various synthetic processes (i.e., by wittig and wittig homer reaction), The said journal also discloses a process for the preparation of aldehyde side chain of HMG-CoA reductase inhibitors.
U.S. Pat. No. 4,977,279 incorporated herein by reference, this patent discloses derivatives of 3-demethylmevalonic acid. This patent also teaches the process for the preparation of pyridine and pyrimidine derivatives of demethylmevalonic acid.
U.S. Pat. No. 4,970,313 incorporated herein by reference, discloses process for the preparation of optically active 3-demethylmevalonic acid derivatives via β-hydroxy lactone and also disclosed the protected aldehyde side chain of Statin compounds.
The alternate method for the preparation of olefinic compounds is Julia classical olefination, Julia modified olefination, Julia modified olefination process for the preparation of HMG CoA Reductase inhibitors, is disclosed and claimed in U.S. Pat. No. 6,875,867 incorporated herein by reference, in this patent chiral diol sulfone (aliphatic chain of statins) intermediates used for the preparation of HMG CoA reductase inhibitors, the disclosed chiral diol sulfones are not stable and low yields were observed when using aliphatic chiral diol sulfones when compare to aromatic sulfone derivatives.
International publication WO 2001/60804 incorporated herein by reference, discloses a process for the preparation of amorphous form of rosuvastatin calcium from amine salt which gives high pure rosuvastatin calcium. The amine salt can be recrystallized to get highest purity. The said patent also discloses a process for the preparation of amine salt from an acid.
International publication WO 2004/014872 incorporated herein by reference, discloses a process for the preparation of calcium salt of rosuvastatin. The process comprises, mixing of calcium chloride with a solution of water soluble salt of rosuvastatin like sodium salt, methylamine salt, tris salt and ammonium salt wherein the process parameters are selected to give a product which demonstrates improved efficiency of filtration.
International publication WO2004/108691 incorporated herein by reference, discloses a process for an improved production of rosuvastatin calcium salt which discloses the usage of calcium chloride, calcium bromide and calcium acetate as a calcium source for the preparation of rosuvastatin calcium.
International publication WO 2005/042522 incorporated herein by reference, the said patent claims crystalline form of dihydroxy and olefin compound of rosuvastatin ester.
International publication WO 2005/054207 incorporated herein by reference, discloses an alternate process for the preparation of rosuvastatin and its intermediates via wittig reagents. The process involved the condensation of wittig reagent like triphenyl[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylmethyl]phosphonium bromide or other reagent with aldehyde side chain compound tert-butyl2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dixan-4-yl}acetate in a suitable solvent and in presence of a base to give tertiarybutyl ester compound of rosuvastatin which is further converted into free acid then to calcium salt by contacting calcium source. This process suffers from quality aspects as Z isomer formation is high (i.e., approximately 20%) in witting reactions.
International publication WO 2005/077916 incorporated herein by reference, discloses crystalline cyclohexyl ammonium, diisopropyl ammonium, isopropyl ammonium, dicyclohexyl ammonium(S)-(+)-methylbenzyl ammonium salts of rosuvastatin and process for their preparation. The said patent also discloses process for the preparation of amorphous rosuvastatin calcium from generic amine salt of rosuvastatin and the PXRD pattern of amorphous form of rosuvastatin calcium.
International publication WO 2006/035277 incorporated herein by reference, discloses a process for the preparation of amorphous form of rosuvastatin calcium and novel crystalline form A of rosuvastatin calcium and also disclosed the PXRD pattern of both crystalline and amorphous form of rosuvastatin calcium salt.
International publication WO 2006/079611 incorporated herein by reference, discloses a novel crystalline form B and C of rosuvastatin calcium salt hydrates and process for their preparation. The disclosed PXRD pattern of the Form C is similar to the disclosed amorphous form of rosuvastatin calcium.
International publication WO 2006/136407 incorporated herein by reference, disclosed a pure amorphous form of rosuvastatin calcium having HPLC purity more than 99.9% and free from any traces of alkali metal impurities. The said patent also discloses process for the preparation of amorphous rosuvastatin calcium, which comprises of reacting the tertiary butyl ester of rosuvastatin with organic amine salt to get pure amorphous rosuvastatin calcium. The international publication WO 2001/60804 is also disclosed process for the preparation of pure amorphous rosuvastatin calcium from organic amine salt compound.
International publication WO 2007/000121 incorporated herein by reference, discloses a process for the preparation of hemi-calcium salt of rosuvastatin in crystalline or amorphous solid state. The process comprises of hydrolyzing the alkyl ester or amides of rosuvastatin and converting the obtained alkali salt into calcium salt of rosuvastatin by reacting with suitable calcium source in aqueous medium followed by extracting the crude rosuvastatin calcium into a solvent partially miscible with water, washing with water and isolating by cooling and filtration or by adding anti-solvent and filtration or spray drying into the stream of inert gas.
International publication WO 2007/040940 incorporated herein by reference, discloses a process for the preparation of diasteriomerically pure rosuvastatin and intermediates.
International publication WO 2007/041666 incorporated herein by reference, discloses a process for the preparation of rosuvastatin calcium by employing witting homer reaction.
It is, therefore, desirable to provide an efficient process for the preparation of statins which improves the economics by employing less expensive reagents and is more productive compare to the known processes.
The present invention provides a novel and advantageous process for the preparation of calcium salt of statins which solves solubility problem of the compound in an aqueous methanol and gives free flow solid of calcium salt. The present invention uses calcium acetate instead of calcium chloride so the byproduct is sodium acetate, which is highly soluble in water. So the obtained compound is freely soluble in methanol.
The present invention provides a process which involves less number of steps, without isolation of intermediate, eco-friendly, easy to scale-up and commercially viable for the preparation of statins and its pharmaceutically acceptable salts thereof.
Disadvantages of the Prior Art Processes:
    • Usage of hazardous reagents like phosphorous trihalides or phosphorous oxyhalides.
    • Usage of strong base like LDA/n-BuLi followed by usage of Na/Hg in Julia classical olefination reactions, which are highly pyrophoric in nature, hence those are not recommended for commercial scale up.
    • Usage of strong base like LDA/n-BuLi in Julia modified olefination reactions, which are highly pyrophoric in nature, hence those are not recommended for commercial scale up.
    • Chiral diol sulfone compounds which are prepared as per the procedure given in U.S. Pat. No. 6,875,867 are unstable intermediates.
    • Poor solubility of calcium salt compound of formula-1 in an aqueous methanol.
    • Z isomer content is high in the rosuvastatin calcium prepared as per the prior art.
BRIEF DESCRIPTION OF THE INVENTION
In accordance with the present invention, a process is provided for preparing chiral dihydroxy acid HMG CoA reductase inhibitors which are useful as anti-cholesterol agents as described hereinafter.
The present invention provides a novel process for the preparation of statins and its pharmaceutically acceptable salts compound of general formula-1 and general formula-2
Figure US08455640-20130604-C00009
wherein
Figure US08455640-20130604-P00003
denotes single or double bond and M is H, Na+, K+, Mg+2, Ca+2 and R, R1 is defined as above.
The first aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts represented by general formula-1, which comprises of the following steps
    • a) Reacting the sulfone compound of general formula-3 with an aldehyde compound of formula-4 in presence of a suitable alkali base in a suitable solvent to give condensed product, which in-situ reaction with a suitable acid in a suitable aqueous solvent followed by basic hydrolysis of the obtained product in suitable aqueous solvent then treatment with suitable organic amine in a suitable solvent gives organic amine compound of general formula-5, followed by purifying in a suitable solvents gives the pure organic amine compound of general formula-5,
    • b) Converting the organic amine compound of general formula-5 into its pharmaceutically acceptable salt of general formula-1 by treating the organic amine compound of general formula-5 with an alkali base, optionally isolating the corresponding alkali salt compound of general formula-6 followed by treating with alkali or alkaline earth metal salts in a suitable solvent.
The second aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts represented by general formula-1, which comprises of the following steps
    • a) Reacting sulfone compound of general formula-3 with an amide compound of general formula-7 in presence of an alkali and alkaline earth metal bases in a suitable polar aprotic solvent to provide compound of general formula-8, which in-situ reacting with suitable acid to form diol compound of general formula-9, which upon treating with base such as an alkali metal hydroxide to form corresponding alkali metal salt then further treating with an organic amine base to give organic amine compound of general formula-5,
    • b) Converting the organic amine compound of general formula-5 into its pharmaceutically acceptable salt of general formula-1 by treating the organic amine compound of general formula-5 with an alkali base, optionally isolating the corresponding alkali salt compound of general formula-6 followed by treating with alkali or alkaline earth metal salts in a suitable solvent.
The third aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts represented by general formula-1, which comprises of the following steps
    • a) Reacting the sulfone compound of general formula-3 with an aldehyde compound of formula-4 in presence of an alkali and alkaline earth metal bases in a suitable solvent to provide the condensed compound, which in-situ reacting with suitable acid to give the lactone compound which is further reacting with suitable organic amine to give an amide compound of general formula-10,
    • b) Reacting the amide compound of general formula-10 with suitable base followed by reacting with suitable organic amine to give an organic amine compound of general formula-5,
    • c) Converting the organic amine compound of general formula-5 into its pharmaceutically acceptable salt of general formula-1 by treating the organic amine compound of general formula-5 with an alkali base, optionally isolating the corresponding alkali salt compound of general formula-6 followed by treating with alkali or alkaline earth metal salts in a suitable solvent.
The fourth aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts represented by general formula-1, which comprises of the following steps
    • a) Reacting sulfone compound of general formula-3 with an aldehyde compound of formula-4 in presence of an alkali and alkaline earth metal bases in a suitable polar aprotic solvent to provide a compound of general formula-11, which in-situ reacting with suitable acid to form diol compound of general formula-12, which upon treating with a base such as an alkali metal hydroxide to form corresponding alkali metal salt then further treating with an organic amine base to give organic amine compound of general formula-5,
    • b) Converting the organic amine compound of general formula-5 into its pharmaceutically acceptable salt of general formula-1 by treating the organic amine compound of general formula-5 with an alkali base, optionally isolating the alkali salt of corresponding compound of general Formula-6 followed by treating with corresponding alkali or alkaline earth metal salts in a suitable solvent.
The fifth aspect of the present invention is to provide a novel process for the preparation of olefin dihydroxy compound of general formula-2 via a Julia-Modified olefination, which comprises of the following steps
    • a) Reacting the sulfone compound of general formula-13 with an aldehyde compound of general formula-14 in presence of an alkali and alkaline earth metal bases in a suitable polar aprotic solvent to provide olefin compound of general formula-15,
    • b) The olefin compound of general formula-15 may be used to form a dihydroxy acid (or lactam thereof) HMG CoA reductase inhibitor by subjecting the olefin compound of formula-15 to acidic conditions to remove the acetonide and form diol compound, which upon treating with a base such as an alkali metal hydroxide to form the corresponding alkali metal salt then further treating with an organic amine base to form corresponding organic amine compound of general formula-16,
    • c) Converting the organic amine compound of general formula-16 into free acid compound of formula-21 by treating the organic amine compound of general formula-6 with an acid to give an acid compound of formula-21,
    • d) The alkenyl double bond in acid compound of formula-21 may be hydrogenated (H2/Pd/C) to provide the saturated alkyl acid compound of formula-22,
    • e) Converting the dihydroxy acid compound or its organic amine salt into its pharmaceutically acceptable salts of the general formula-2 by treating the organic amine compound of general formula-16 or acid compound of general formula-21 with an alkali base followed by treating with corresponding alkali or alkaline earth metal salts in a suitable solvent.
      The lactone compound of formula-23 may be prepared
Figure US08455640-20130604-C00010
by treating the olefin compound of formula-15 under acid conditions (for example, TFA, HCl) to effect conversion to lactone compound of formula-23. The saturated derivative of lactone compound of formula-23 may be obtained by catalytic (Pd/C, Pt/C, Pd(OH)2) hydrogenation of compound of formula-23 to compound of formula-24.
Figure US08455640-20130604-C00011
Lactone compounds of formula-23 and formula-24 may be converted to the corresponding diol compounds by saponification of formula-23 and formula-24 with aqueous base to form corresponding alkali salt compounds of formula-25 and formula-26
Figure US08455640-20130604-C00012
The sixth aspect of the present invention is to provide a novel process for the preparation of olefin dihydroxy compound of general formula-2 is provided via a Julia-Modified olefination, which comprises of the following steps
    • a) Reacting a sulfoxide compound of general formula-17 with an aldehyde compound of general formula-14 in presence of an alkali and alkaline earth metal bases in a suitable polar aprotic solvent to provide olefin compound of general formula-15,
    • b) The olefin compound of general formula-15 may be used to form a dihydroxy acid (or lactam thereof) HMG CoA reductase inhibitor by subjecting olefin compound of general formula-15 to acidic conditions to remove the acetonide and form diol compound, which upon treating with a base such as an alkali metal hydroxide to form corresponding alkali metal salt then further treating with an organic amine base to form corresponding organic amine compound of general formula-16,
    • c) Converting the organic amine compound of general formula-16 into free acid compound of formula-21 by treating the organic amine compound of general formula-16 with an acid to give an acid compound of formula-21,
    • d) The alkenyl double bond in acid compound of formula-21 may be hydrogenated (H2/Pd/C) to provide the saturated alkyl acid compound of formula-22,
    • e) Converting the dihydroxy acid compound or its organic amine salt into its pharmaceutically acceptable salts of general formula-2 by treating the organic amine compound of general formula-16 or an acid compound of general formula-21 with an alkali base followed by treating with corresponding alkali or alkaline earth metal salts in a suitable solvent.
The seventh aspect of the present invention is to provide a novel process for preparing a novel sulfone and sulfoxide compounds having general Formula-13 and general formula-17, which comprises of the following steps
    • a) Reacting a compound of general formula-18 with a thiol compound of general formula-19 in presence of a suitable base with or without a suitable solvent to provide a novel sulfide compound of general formula-20,
    • b) And oxidizing the sulfide compound of formula-20 with an oxidizing agent in presence of an appropriate catalyst in a suitable solvent, to provide a novel sulfone compound of general Formula-13 and sulfoxide compound of formula-17 can be prepared by controlled oxidation of sulfide.
The eighth aspect of the present invention is to provide a novel process for the preparation of calcium salt of statins compounds of general formaula-1 and compound of general formula-2, which comprises of the following steps.
    • a) Converting the organic amine salt compound of general formula-5 or general formula-16 into its corresponding alkali salt by treating with alkali base;
    • b) Setting the reaction mixture pH to 8.0 to 9.2 by evaporating the solvent containing organic amine under nitrogen atmosphere followed by extraction or by extracting the organic amine with a suitable solvent or by adding an acid,
    • c) Adding the aqueous phase of the reaction mixture to a calcium source to give free flow calcium salt compound of general formula-1 or general formula-2.
Figure US08455640-20130604-C00013
Wherein M is Calcium and R1 is defined as above
In addition, in accordance with the present invention, the following intermediates prepared by the process of the invention are novel compounds;
1. Sulfide compounds of general formula-20
Figure US08455640-20130604-C00014
Wherein R1 is as defined above and is linked to sulphur atom with a methylene group and R2 is as defined above.
2. Sulfone compounds of general Formula-13
Figure US08455640-20130604-C00015
Wherein R1 is as defined above which is linked to sulphur atom with a methylene group (—CH2—) and R2 is as defined above.
3. Sulfoxide compounds of general formula-13
Figure US08455640-20130604-C00016
Wherein R1 is as defined above which is linked to sulphur atom with a methylene group (—CH2—) and R2 is as defined above.
ADVANTAGES OF THE PRESENT INVENTION
    • No pyrophoric reagents used in present invention.
    • Usage of simple bases like potassium carbonate, sodium carbonate instead of using LDA/n-BuLi/LiHMDS/NaHMDS.
    • Sulfone compounds which are prepared as per the present invention are stable,
    • Yields are above 80% for all stages of the present invention.
    • Calcium salt compound of formula (1a) is freely soluble in an aqueous methanol,
    • Calcium slat compounds of statins prepared by the present invention are free flow solids.
    • Provides One-pot process for the preparation of statins
    • Provides a novel process using a novel amide intermediates
    • Z isomer impurity level is nil in rosuvastatin calcium obtained by the present invention
    • The present invention is simple and cost effective.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1: Illustrates the powder X-ray diffraction pattern of rosuvastatin tertiarybutyl amine
FIG. 2: Illustrates the powder X-ray diffraction pattern of amorphous rosuvastatin calcium.
 DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, novel process is provided for the preparation of chiral dihydroxy acid HMG CoA reductase inhibitors which are useful as anti-cholesterol agents as described hereinafter.
The present invention provides a novel process for the preparation of statins and its pharmaceutically acceptable salts compounds of general formula-1 and general formula-2,
Figure US08455640-20130604-C00017
Wherein R is a hydrophobic anchor or residue of an HMG CoA reductase inhibitor and may for example be
Figure US08455640-20130604-C00018
Wherein M is H, Na+, K+, Mg+2, Ca+2
Herein after the above compounds of formula A, B and C are referred as ‘R’,
Figure US08455640-20130604-C00019
Wherein R1 is a hydrophobic anchor or residue of an HMG CoA reductase inhibitor and may for example be
Figure US08455640-20130604-C00020
Figure US08455640-20130604-C00021
wherein ‘
Figure US08455640-20130604-P00004
’ denotes single or double bond and M is H, Na+, K+, Mg+2, Ca+2
Herein after the above compounds of formula (a),(b),(c),(d),(e),(i),(g) and (h) are referred as ‘R1’.
The first aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by the general formula-1,
Figure US08455640-20130604-C00022
wherein M is H, Na+, K+, Mg+2, Ca+2 and R is defined as above
Which comprises of the following steps
    • a) Reacting the sulfone compound of general formula-3
Figure US08455640-20130604-C00023
      • Wherein R is defined as above which is linked to sulphur atom with a methylene group (—CH2—) and R2 is
Figure US08455640-20130604-C00024
      • Wherein
      • R3 is alkyl, aryl, arylalkyl or cycloalkyl,
      • R4 is H, alkyl, aryl, arylalkyl, CF3, halo or NO2
      • R5 is H, alkyl, alkaoxy, haloalkyl, monohaloalkyloxy, dihaloalkyloxy
      • And
      • X is O,N—H,N-alkyl or S;
      • with an aldehyde compound of formula-4
Figure US08455640-20130604-C00025
      • in presence of an alkali and alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably potassium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethyl acetamide and/or toluene and/or mixtures thereof, preferably dimethyl sulfoxide gives condensed product, which in-situ reacting with trifluoroacetic acid in a suitable solvent like aqueous acetonitrile followed by basic hydrolysis of the obtained product in aqueous acetonitrile which is further reacting with suitable organic amine base in a suitable solvent to give the organic amine compound of general Formula-5 followed by the purification in a suitable alcohol solvents like methanol, ethanol and isopropyl alcohol and/or acetonitrile and/or mixtures thereof to give pure organic amine compound of general formula-5,
Figure US08455640-20130604-C00026
      • Organic amine selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine,
    • b) Converting the corresponding organic amine compound of general formula-5 into its pharmaceutically acceptable salts of general formula-1 by treating the organic amine salt compound of general formula-5 with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the organic amine salt compound of general formula-5 with tertiary butyl acetate or by direct distillation of the reaction mixture,
    • c) Optionally isolating the alkali, salt of corresponding compound of general formula-6,
Figure US08455640-20130604-C00027
      • wherein M is Na+, K+,
    • d) Adding the aqueous phase of the reaction mixture or an aqueous solution of isolated alkali salt compound of general formula-6 to a solution of calcium chloride or calcium acetate in a suitable solvent such as water.
The second aspect of the present invention is to provide a one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by general formula-1
Figure US08455640-20130604-C00028
wherein M is H, Na+, K+, Mg+2, Ca+2 and R is defined as above
Which comprises of the following steps
    • a) Reacting the sulfone compound of general formula-3
Figure US08455640-20130604-C00029
      • Wherein R is defined as above which is linked to sulphur atom with a methylene group (—CH2—) and R2 is defined as above
      • with an amide compound of general formula-7
Figure US08455640-20130604-C00030
      • Wherein R6 and R7 are C1-C10 straight or branched chain alkyl or cycloalkyl or cycloalkyl with one heteroatom,
      • in presence of an alkali and alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably potassium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethylacetamide or mixtures thereof, preferably dimethyl sulfoxide to provide the compound of general formula-8,
Figure US08455640-20130604-C00031
      • which in-situ reacting with suitable acid such as hydrochloric acid, acetic acid, sulfuric acid in a suitable solvent to give the diol compound of general formula-9,
Figure US08455640-20130604-C00032
      • which upon treating with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide to form the corresponding alkali salt then further treating with suitable organic amine base to give organic amine compound of general formula-5,
Figure US08455640-20130604-C00033
      • Organic amine selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine,
    • b) Converting the corresponding organic amine compound of general formula-5 into its pharmaceutically acceptable salts of general formula-1 by treating the organic amine compound of general Formula-5 with an alkali base such as sodium hydroxide, potassium hydroxide and lithium, hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the organic amine salt compound of general Formula-5 with tertiary butyl acetate or by direct distillation of the reaction mixture,
    • c) Optionally isolating the corresponding alkali salt compound of general formula-6,
Figure US08455640-20130604-C00034
      • wherein M is Na+, K+
    • e) Adding the aqueous phase of the reaction mixture or an aqueous solution of isolated alkali salt compound of general formula-6 to a solution of calcium chloride or calcium acetate in a suitable solvent such as water.
The third aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by general formula-1
Figure US08455640-20130604-C00035
wherein R is defined as above and M is H, Na+,K+,Mg+,Ca+2
Which comprises of the following steps
    • a) Reacting the sulfone compound of general formula-3
Figure US08455640-20130604-C00036
      • Wherein R is defined as above which is linked to sulphur atom with a methylene group (—CH2—) and R2 is defined as above
      • With an aldehyde compound of formula-4
Figure US08455640-20130604-C00037
      • in presence of an alkali and alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably potassium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethyl acetamide or mixtures thereof, preferably dimethyl sulfoxide to provide condensed compound, which in-situ reacting with trifluoroacetic acid to give the lactone compound, which is further reacting with suitable organic amine to give an amide compound of general formula-10
Figure US08455640-20130604-C00038
      • Wherein R8 and R9 are C1-C10 straight or branched chain alkyl or cycloalkyl or cycloalkyl with one heteroatom,
    • b) Reacting the amide compound of general formula-10 with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide followed by treating with suitable organic amine base to give organic amine compound of general formula-5,
Figure US08455640-20130604-C00039
      • Organic amine selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, morpholine and pyrrolidine,
    • c) Converting the corresponding organic amine compound of general formula-5 into its pharmaceutically acceptable salts of general formula-1 by treating the organic amine salt compound of general formula-5 with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the organic amine salt compound of general Formula-5 with tertiary butyl acetate or by direct distillation of the reaction mixture,
    • d) Optionally isolating the corresponding alkali salt compound of general formula-6,
Figure US08455640-20130604-C00040
      • wherein M is Nat, K+
    • f) Adding the aqueous phase of the reaction mixture or an aqueous solution of isolated alkali salt compound of general Formula-6 to a solution of calcium chloride or calcium acetate in a suitable solvent such as water.
The fourth aspect of the present invention is to provide one-pot synthesis for the preparation of statins and its pharmaceutically acceptable salts thereof represented by general formula-1,
Figure US08455640-20130604-C00041
wherein M is H, Na+,K+,Mg+2,Ca+2 and R is defined as above
Which comprises of the following steps
    • a) Reacting the sulfone compound of general formula-3
Figure US08455640-20130604-C00042
      • Wherein R is defined above which is linked to sulphur atom with a methylene group (—CH2—) and R2 is defined as above
      • with an aldehyde compound of Formula-4
Figure US08455640-20130604-C00043
      • in presence of an alkali and alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably potassium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethylacetamide or mixtures thereof, preferably dimethyl sulfoxide to provide the compound of general formula-11,
Figure US08455640-20130604-C00044
      • which in-situ reacting with suitable acid such as hydrochloric acid, acetic acid, sulfuric acid in a suitable solvent to give the diol compound of general formula-12,
Figure US08455640-20130604-C00045
      • which upon treating with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide to form the corresponding alkali base salt then further treating with an suitable organic amine base to give organic amine compound of general formula-5,
Figure US08455640-20130604-C00046
      • Organic amine selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine.
    • b) Converting the corresponding organic amine compound of general formula-5 into its pharmaceutically acceptable salts of general formula-1 by treating the organic amine compound of general formula-5 with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the organic amine salt compound of general formula-5 with tertiary butyl acetate or by direct distillation of the reaction mixture,
    • c) Optionally isolating the corresponding alkali salt compound of general formula-6,
Figure US08455640-20130604-C00047
      • wherein M is Na+, K+
    • d) Adding the aqueous phase of the reaction mixture or an aqueous solution of isolated alkali salt compound of general formula-6 to a solution of calcium chloride or calcium acetate in a suitable solvent such as water.
The fifth aspect of the present invention is to provide a novel process for the preparation of olefinic dihydroxy compound of general formula-2 via a Julia-Modified olefination, which comprises of the following steps
    • a) Reacting a sulfone compound of general formula-13
Figure US08455640-20130604-C00048
      • Wherein R1 is defined as above which is linked to sulphur atom with a methylene group (—CH2—) and R2 is
Figure US08455640-20130604-C00049
      • Wherein
      • R3 is alkyl, aryl, arylalkyl or cycloalkyl,
      • R4 is H, alkyl, aryl, arylalkyl, CF3, halo or NO2
      • R5 is H, alkyl, alkaoxy, haloalkyl, monohaloalkyloxy, dihaloalkyloxy
      • And
      • X is O,N—H,N-alkyl or S;
      • Herein after the above compounds of general formula (i), (j) and (k) are referred as ‘R2’
      • with an aldehyde compound of general formula-14
Figure US08455640-20130604-C00050
      • wherein R10 is alkyl,cycloalkyl,arylalkyl,aryl or carbonylbenzyloxy (cbz), preferably alkyl, more preferably tertiary butyl,
      • in presence of an alkali and alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably cesium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethylacetamide or mixtures thereof, preferably dimethyl sulfoxide to provide olefin compound of general formula-15,
Figure US08455640-20130604-C00051
    • b) The olefin compound of general formula-15 may be used to form a dihydroxy acid HMG CoA reductase inhibitor by subjecting olefin compound of formula-15 to acidic conditions such as using hydrochloric acid, acetic acid, sulfuric acid to remove the acetonide and form diol compound, which upon treating with an alkali base such as sodium hydroxide to form the corresponding sodium salt then further treating with suitable organic amine base to give organic amine compound of formula-16,
Figure US08455640-20130604-C00052
      • Organic amine selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine,
    • c) Converting the corresponding organic amine compound of general formula-16 into its pharmaceutically acceptable salts of general formula-2 by treating the organic amine compound of general formula-16 with an alkali base such as sodium hydroxide followed by treating with corresponding alkali or alkaline earth metal salts like calcium chloride, calcium acetate, sodium hydroxide, potassium hydroxide in a suitable solvent such as water.
Figure US08455640-20130604-C00053
      • wherein M is H, Na+, K+, Mg+2, Ca+2 and R1 is defined as above.
The sixth aspect of the present invention is to provide a novel process for the preparation of olefin dihydroxy compound of formula-2 via a Julia-Modified olefination, which comprises of the following steps,
    • a) Reacting sulfoxide compound of general formula-17
Figure US08455640-20130604-C00054
      • with an aldehyde compound of general Formula-14
Figure US08455640-20130604-C00055
      • wherein R10 is alkyl,cycloalkyl,arylalkyl,aryl or carbonylbenzyloxy (cbz), preferably alkyl, more preferably tertiary butyl,
      • in presence of strong base like amide bases such as sodium bis(trimethyl silyl) amide, potassium bis(trimethyl silyl) amide, lithium bis(trimethyl silyl) amide in a suitable polar aprotic solvents like dimethylformamide, dimethylsulfoxide, dimethylacetamide or mixtures thereof, preferably dimethyl sulfoxide to provide olefin compound of general formula-15,
Figure US08455640-20130604-C00056
    • b) The olefin compound of general formula-15 may be used to form a dihydroxy acid HMG CoA reductase inhibitor by subjecting olefin compound of general formula-15 to acidic conditions such as using hydrochloric acid, sulfuric acid, acetic acid to remove the acetonide and form diol compound, which upon treating with an alkali base such as sodium hydroxide to form the corresponding sodium salt then further treating with suitable organic amine base compound to give the organic amine compound of general formula-16,
Figure US08455640-20130604-C00057
      • Organic amine selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine,
    • c) Converting the corresponding organic amine compound of general formula-16 into its pharmaceutically acceptable salts of general formula-2 by treating the organic amine compound of general formula-16 with an alkali base such as sodium hydroxide followed by treating with corresponding alkali or alkaline earth metal salts like calcium chloride, calcium acetate, sodium hydroxide in a suitable solvent such as water.
Figure US08455640-20130604-C00058
      • where M is H, Na+, K+, Mg+2, Ca+2 and R1 is defined as above.
The seventh aspect of the present invention is to provide a process for the preparation of a novel sulfone compound of general formula-13 and sulfoxide derivative compound of general formula-17,
Figure US08455640-20130604-C00059
Wherein R1 is defined as above which is linked to sulphur atom with a methylene group (—CH2—) and R2 is defined as above,
which comprises of the following steps
    • a) Treating a solution of the compound of general formula-18
      R1-L  Formula-18
      • Wherein L is a leaving group such as halogen, trifluoromethanesulfonyloxy, methanesulfonyloxy, preferably halogen, more preferably bromo and R1 is defined as above which is linked to leaving group with a methylene group (—CH2—)
      • with a thiol compound of general formula-19
        R2SH  Formula-19
      • wherein R2 is defined as above
      • in presence of a suitable base like sodium hydroxide with or without a suitable solvent, a suitable solvent selected from chloro solvents like methylene chloride, chloroform, carbon tetrachloride, keto solvents like acetone, 2-butanone, methyl isobutyl ketone, methyl ethyl ketone, ester solvents like ethyl acetate, methyl acetate, tertiary butyl acetate, polar solvents like dimethyl formamide, dimethyl acetamide, dimethyl sulfoxide, water or mixtures thereof, preferably keto solvents, more preferably acetone to provide a novel sulfide compound of formula-20
Figure US08455640-20130604-C00060
      • wherein R1 is defined as above which is linked to sulphur atom with a methylene group (—CH2—) and R2 are defined as above
    • b) And oxidizing a sulfide compound of formula-20 with an oxidizing agent like metachloro per benzoic acid, sodium hypochlorite, hydrogen peroxide, tertiary butyl hydrogen peroxide, cumene hydro peroxide, preferably hydrogen peroxide in the presence of an appropriate catalyst like ammonium molybdate in a single or biphasic system in a suitable solvent selected from alcoholic solvents like methanol, 2-proponol, ethanol, chloro solvents like methylene chloride, chloroform, carbon tetra chloride or mixture thereof, preferably chloro solvents, more preferably methylene chloride to provide the novel sulfone compound of general formula-13 and a novel sulfoxide compound of formula-17 can be prepared by controlled oxidation of sulfide.
The Eighth aspect of the present invention is to provide a novel, process for the preparation of calcium salt compound of general formula-1 and general formula-2,
Figure US08455640-20130604-C00061
Wherein M is Calcium and R1 is defined as above.
Which comprises of the following steps
    • a) Converting the organic amine salt compound of general formula-5 or Formula-16 into its sodium salt by treating with sodium hydroxide,
    • b) Setting the reaction mixture pH to 8.0 to 9.2 by evaporating the solvent containing organic amine under nitrogen atmosphere followed by extracting the reaction mixture with a suitable solvent such as ester solvents like ethyl acetate, methyl acetate, tertiary butyl acetate or by extracting the organic amine with a suitable solvent like ester solvents ethyl acetate, methyl acetate, tertiary butyl acetate, preferably tertiary butyl acetate to remove organic amine or by adding an acid like hydrochloric acid,
    • c) Adding the aqueous phase of the reaction mixture to a calcium source like calcium chloride or calcium acetate in a suitable solvent like water to give free flow calcium salt compound of general formula-1 or formula-2 respectively.
According to the present invention, a preferred one-pot synthesis is provided for the preparation of rosuvastatin calcium salt compound of formula-1A, which comprises of the following steps
    • a) Reacting the sulfone compound of formula-3A
Figure US08455640-20130604-C00062
      • With an aldehyde compound of formula-4
Figure US08455640-20130604-C00063
      • in presence of an alkali and alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably potassium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethyl acetamide and/or toluene and/or mixtures thereof, preferably dimethyl sulfoxide gives condensed product, which in-situ reacting with trifluoroacetic acid in a suitable solvent like aqueous acetonitrile followed by basic hydrolysis of the obtained product in aqueous acetonitrile which is further reacting with suitable organic amine base like tertiarybutyl amine in a suitable solvent like acetonitrile to give the rosuvastatin tertiarybutyl amine compound of formula-5A followed by the purification in a suitable alcohol solvents like methanol, ethanol and isopropyl alcohol and/or acetonitrile and/or mixtures thereof preferably in a mixture of acetonitrile and isopropyl alcohol to give pure rosuvastatin tertiarybutyl amine compound of formula-5A,
Figure US08455640-20130604-C00064
    • b) Converting the rosuvastatin tertiarybutyl amine compound of formula-5A into its calcium salt compound of formula-1A by treating the tertiarybutyl amine compound of formula-5A with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide preferably sodium hydroxide or potassium hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the organic amine salt compound of formula-5A with tertiarybutyl acetate or by direct distillation,
    • c) Optionally isolating the corresponding sodium or potassium salt of rosuvastatin compound of formula-6A or 6AA,
Figure US08455640-20130604-C00065
    • d) Adding the aqueous phase of the reaction mixture or an aqueous solution of rosuvastatin sodium or potassium salt to a solution of calcium chloride or calcium acetate in a suitable solvent such as water.
According to the present invention, a preferred one-pot synthesis is provided for the preparation of rosuvastatin calcium salt compound of formula-1A, which comprises of the following steps
    • a) Reacting the sulfone compound of formula-3A
Figure US08455640-20130604-C00066
      • With an amide compound of formula-7A
Figure US08455640-20130604-C00067
      • in presence of an alkali and alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably potassium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethylacetamide or mixtures thereof, preferably dimethyl sulfoxide to provide the compound of general formula-8A,
Figure US08455640-20130604-C00068
      • which in-situ reacting with suitable acid such as hydrochloric acid, acetic acid, sulfuric acid in a suitable solvent to give the diol compound of general formula-9A,
Figure US08455640-20130604-C00069
      • which upon treating with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide to form the corresponding alkali salt then further treating with an organic amine base like n-butyl amine, isobutyl amine, (+/−) 2-butyl amine, tertiarybutyl amine preferably tertiarybutyl amine to give rosuvastatin tertiarybutyl amine compound of formula-5A,
Figure US08455640-20130604-C00070
    • b) Converting rosuvastatin tertiarybutyl amine compound of formula-5A into its rosuvastatin calcium compound of formula-1A by treating the tertiarybutyl amine compound of formula-5A with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide preferably sodium hydroxide or potassium hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the rosuvastatin tertiarybutyl amine salt compound of formula-5A with tertiary butyl acetate or by direct distillation,
    • c) Optionally isolating the corresponding sodium or potassium salt of rosuvastatin compound of formula-6A or 6AA,
Figure US08455640-20130604-C00071
    • d) Adding the aqueous phase of the reaction mixture or an aqueous solution of rosuvastatin sodium or potassium salt to a solution of calcium chloride or calcium acetate in a suitable solvent such as water.
According to the present invention, a preferred one-pot synthesis is provided for the preparation of rosuvastatin calcium salt compound of formula-1A
Figure US08455640-20130604-C00072
which comprises of the following steps
    • a) Reacting the sulfone compound of Formula-3A
Figure US08455640-20130604-C00073
      • With an aldehyde compound of formula-4
Figure US08455640-20130604-C00074
      • in presence of an alkali and alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably potassium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethylacetamide or mixtures thereof, preferably dimethyl sulfoxide to provide condensed compound, which in-situ reacting with trifluoroacetic acid to give the lactone compound, which is further in-situ reacting with diisopropylamine to give the diisopropyl amide compound of formula-10A,
Figure US08455640-20130604-C00075
    • a) Reacting the diisopropyl amide compound of formula-10A with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide followed by treating with an organic amine base like n-butyl amine, isobutyl amine, (+/−) 2-butyl amine, tertiarybutyl amine, preferably tertiarybutyl amine to give rosuvastatin tertiarybutyl amine compound of formula-5A,
Figure US08455640-20130604-C00076
    • c) Converting the rosuvastatin tertiarybutyl amine compound of formula-5A into rosuvastatin calcium salt compound of formula-1A by treating the rosuvastatin tertiarybutyl amine compound of formula-5A with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide preferably sodium hydroxide or potassium hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the rosuvastatin tertiarybutyl amine with tertiary butyl acetate or by direct distillation,
    • d) Optionally isolating the corresponding sodium or potassium salt of rosuvastatin compound of formula-6A or 6AA,
Figure US08455640-20130604-C00077
    • e) Adding the aqueous phase of the reaction mixture or an aqueous solution of rosuvastatin sodium or potassium salt to a solution of calcium chloride or calcium acetate in a suitable solvent such as water.
According to the present invention, a preferred one-pot synthesis is provided for the preparation of rosuvastatin calcium salt compound of formula-1A
Figure US08455640-20130604-C00078
The one-pot synthesis for the preparation of rosuvastatin calcium compound of formula-1A comprises of the following steps
    • a) Reacting the sulfone compound of formula-3A
Figure US08455640-20130604-C00079
      • With an aldehyde compound of formula-4
Figure US08455640-20130604-C00080
      • in presence of an alkali and/or alkaline earth metal bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, and cesium carbonate preferably potassium carbonate in a suitable polar aprotic solvent like dimethylformamide, dimethylsulfoxide, dimethylacetamide or mixtures thereof, preferably dimethyl sulfoxide to provide the compound of formula-11A
Figure US08455640-20130604-C00081
      • which in-situ reacting with suitable acid such as hydrochloric acid, acetic acid, sulfuric acid in a suitable solvent to give the diol compound of formula-12A,
Figure US08455640-20130604-C00082
      • which upon treating with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide to form the corresponding alkali salt then further treating with an organic amine base like n-butyl amine, isobutyl amine, (+/−) 2-butyl amine, tertiarybutyl amine, preferably tertiarybutyl amine to give rosuvastatin tertiarybutyl amine compound of formula-5A,
Figure US08455640-20130604-C00083
    • a) Converting the rosuvastatin tertiarybutyl amine compound of formula-5A into rosuvastatin calcium salt compound of formula-1A by treating the rosuvastatin tertiarybutyl amine compound of formula-5A with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide preferably sodium hydroxide or potassium hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the rosuvastatin tertiarybutyl amine with tertiary butyl acetate or by direct distillation
    • b) Optionally isolating the corresponding sodium or potassium salt of rosuvastatin compound of Formula-6A or 6AA,
Figure US08455640-20130604-C00084
    • d) Adding the aqueous phase of the reaction mixture or an aqueous solution of rosuvastatin sodium or potassium salt to a solution of calcium chloride or calcium acetate in a suitable solvent such as water. Thus obtained amorphous rosuvastatin calcium compound can be milled and/or micronized to get the desired particle size distribution.
According to the present invention, a preferred process is provided for preparing the preferred olefinic chiral dihydroxy acid and its pharmaceutically acceptable salts compound of formula-2a
Figure US08455640-20130604-C00085
A novel process for the preparation of olefin dihydroxy acid is provided via Julia-Modified olefination which comprises of the following steps
    • a) Reacting sulfone compound of formula-13a
Figure US08455640-20130604-C00086
      • With an aldehyde compound of Formula-14a
Figure US08455640-20130604-C00087
      • in the presence of cesium carbonate or potassium carbonate in dimethyl sulfoxide to provide olefin compound of general formula-15a
Figure US08455640-20130604-C00088
    • b) The olefin compound of general formula-15a may be used to form a dihydroxy acid HMG CoA reductase inhibitor by subjecting olefin compound of formula-15a to acidic conditions such as using hydrochloric acid to remove the acetonide and form diol compound, which upon treating with an alkali base such as sodium hydroxide to form sodium salt then further treating with tertiarybutyl amine to form rosuvastatin tertiarybutyl amine compound of formula-16a,
Figure US08455640-20130604-C00089
    • b) Converting the rosuvastatin tertiarybutyl amine compound of formula-16a into rosuvastatin calcium salt compound of formula-2a by treating the rosuvastatin tertiarybutyl amine compound of formula-16a with an alkali base such as sodium hydroxide, potassium hydroxide and lithium hydroxide and setting the pH of the reaction mixture to 9.1 by extracting the rosuvastatin tertiarybutyl amine with tertiary butyl acetate or by direct distillation followed by adding the aqueous phase of the reaction mixture to a solution of calcium chloride or calcium acetate in a suitable solvent such as water.
In accordance with the present invention, a preferred process is provided for preparing the preferred sulfone compound of formula 13a,
Figure US08455640-20130604-C00090
which comprises of the following steps
a) Treating a solution of compound of Formula-18a.
Figure US08455640-20130604-C00091
      • with benzimidazole-thiol compound of formula-19c in presence of sodium hydroxide in dimethyl formamide or in acetone,
Figure US08455640-20130604-C00092
      • to provide a novel sulfide compound of formula-20c
Figure US08455640-20130604-C00093
      • and methylating the compound of formula-20c using methylating agent like dimethyl sulfate to provide N-methyl sulfide compound of formula-27,
Figure US08455640-20130604-C00094
    • b) And oxidizing the sulfide compound of formula-27 with an oxidizing agent like metachloro perbenzoic acid, sodium hypochlorite, hydrogen peroxide, tertiary butyl hydrogen peroxide, cumene hydroperoxide, preferably hydrogen peroxdide in the presence of an appropriate catalyst like ammonium heptamolybdate in a single or biphasic system in a suitable solvent selected from alcoholic solvents like methanol, 2-proponol, ethanol, chlorosolvents like methylene chloride, chloroform, carbon tetra chloride or mixture thereof, preferably chlorosolvents, more preferably methylene chloride or oxidizing the sulfide compound of formula-20c with an oxidizing agent like metachloro perbenzoic acid, sodium hypochlorite, hydrogen peroxide, tertiary butyl hydrogen peroxide, cumene hydroperoxide, preferably hydrogen peroxdide in the presence of an appropriate catalyst like ammonium molybdate in a single or biphasic system in a suitable solvent selected from alcoholic solvents like methanol, 2-proponol, ethanol, chlorosolvents like methylene chloride, chloroform, carbon tetra chloride or mixture thereof, preferably chlorosolvents, more preferably methylene chloride and then methylating the obtained sulfone compound of formula-28, to provide the novel sulfone compound of formula-13a
Figure US08455640-20130604-C00095
In accordance with the present invention, a preferred process is provided for preparing the preferred sulfoxide compound of formula 17a,
Figure US08455640-20130604-C00096
Which comprises of the following steps
    • a) Treating a solution of the compound of formula-18a
Figure US08455640-20130604-C00097
      • with benzimidazole-thiol compound of formula-19c in presence of sodium hydroxide in dimethyl formamide or acetone,
Figure US08455640-20130604-C00098
      • to provide a novel sulfide compound of formula-20c
Figure US08455640-20130604-C00099
      • and methylating the compound of formula-20c using methylating agent to provide N-methyl sulfide compound of formula-27
Figure US08455640-20130604-C00100
    • b) And controlled oxidation of sulfide compound of formula-27 with an oxidizing agent like metachloro perbenzoic acid, sodium hypochlorite, hydrogen peroxide, tertiary butyl hydrogen peroxide, cumene hydroperoxide, preferably hydrogen peroxdide in the presence of an appropriate catalyst like ammonium molybdate in a single or biphasic system in a suitable solvent selected from alcoholic solvents like methanol, 2-proponol, ethanol, chlorosolvents like methylene chloride, chloroform, carbon tetra chloride or mixture thereof, preferably chlorosolvents, more preferably methylene chloride or controlled oxidation of sulfide compound of formula-20c with an oxidizing agent like metachloro perbenzoic acid, sodium hypochlorite, hydrogen peroxide, tertiary butyl hydrogen peroxide, cumene hydroperoxide, preferably hydrogen peroxdide in the presence of an appropriate catalyst like ammonium molybdate in a single or biphasic system in a suitable solvent selected from alcoholic solvents like methanol, 2-proponol, ethanol, chlorosolvents like methylene chloride, chloroform, carbon tetra chloride or mixture thereof, preferably chlorosolvents, more preferably methylene chloride and then methylating the obtained sulfoxide compound of formula-29, to provide novel sulfoxide compound of formula-17c
Figure US08455640-20130604-C00101
The starting material compounds of general formula-13 can be prepared as per the prior art processes, Ref: U.S. Pat. No. 6,627,636; U.S. Pat. No. 5,763,675 (Pitavastatin); U.S. Pat. No. 5,354,772; U.S. Pat. No. 4,739,073 (Fluvastatin); WO 03/097614; US2004/0176401 and WO03/006439.
The starting material aldehyde compound of Formula-13 can be prepared as per the prior art processes, Ref: WO/49014; U.S. Pat. No. 6,844,437; US 20040049036 and in US 2006/0004200 and Tetrahedron Letters, Vol. 31, No. 18, pp 2545-2548, 1990
The process of the present invention may be employed to prepare pravastatin, atorvastatin, cerivastatin, fluvastatin, rosuvastatin, nisvastatin (pitavastatin), simvastatin, lovastatin and other dihydroxy acid or lactone HMG CoA reductase inhibitors.
Following are the impurities generally observed in the process for the preparation of Rosuvastatin calcium.
Figure US08455640-20130604-C00102
The present invention schematically represented by the following schemes
Figure US08455640-20130604-C00103
wherein M is H, Na+,K+,Mg+2,Ca+2 and R1,R2 and R10 is defined as above
Figure US08455640-20130604-P00004
denotes single or double bond
Figure US08455640-20130604-C00104
Figure US08455640-20130604-C00105
Figure US08455640-20130604-C00106
Figure US08455640-20130604-C00107
Figure US08455640-20130604-C00108
Figure US08455640-20130604-C00109
Figure US08455640-20130604-C00110
Figure US08455640-20130604-C00111
Figure US08455640-20130604-C00112
Figure US08455640-20130604-C00113
Figure US08455640-20130604-C00114
Figure US08455640-20130604-C00115
Figure US08455640-20130604-C00116
wherein R1, R2, Organic amine and M is defined as above
Figure US08455640-20130604-C00117
wherein R, R2, R8, R9, organic amine and M is defined as above
Figure US08455640-20130604-C00118
wherein R, R2, R6, R7, Organic amine and M is defined as above
Figure US08455640-20130604-C00119
    • wherein R, R2, organic amine and M is defined as above
Figure US08455640-20130604-C00120
Figure US08455640-20130604-C00121
Figure US08455640-20130604-C00122
Figure US08455640-20130604-C00123
The process for the preparation of amide compound of formula-7 schematically represented by the following scheme-16:
Figure US08455640-20130604-C00124
The processes described in the present invention were demonstrated in examples illustrated below. These examples are provided as illustration only and therefore should not be construed as limitation of the scope of the invention.
EXAMPLES Example-1 Preparation of Sulfide compound of Formula-20a
47.56 grams of 5-(difluoromethoxy)-2-mercapto benzimidazole compound of formula-19a is added to a aqueous sodiumhydroxide solution (9.61 gm sodium hydroxide in 200 ml water) at 25 to 35° C. and stirred for 15 minutes, then added a solution of 400 ml of acetone and 100 grams of [4-(4-Fluoro phenyl)-6-isopropyl-2-(N-Methyl-N-methane sulphonyl amino pyrimidine-5-yl]methyl bromide compound of formula-18a and stirred for 2 hours at 25 to 30° C. Quenched the reaction mass with chilled water and filtered the obtained precipitate and dried the compound at 60-65° C. for 3 hours to get the title compound.
Yield: 119.5 grams; M.R: 165-170° C.
Example-2 Preparation of N-methylated Sulfide Compound of Formula-27a
A solution of 10 grams of sulfide compound of formula-20a prepared as per the example 1 and 100 ml of acetone is cooled to 0-5° C. under nitrogen atmosphere. Added 2.9 grams of potassium carbonate to the above solution then added 3.0 ml of dimethylsulfate to the above reaction mixture and stirred for 4 hours at 0-5° C. Quenched the reaction mixture with chilled water and filtered the precipitated compound. Dried the compound at 50-55° C. for 3 hours.
Yield: 8 grams; M.R: 158-165° C.
Mass spectrum: M+1 peak at 566
Example-3 Preparation of Sulfone Compound of Formula-13a
A solution of 24 grams of N-methylated sulfide compound of formula-27a prepared as per the example 2, 120 ml of methylene chloride and 1.0 grams of tetrabutyl ammonium bromide, is cooled to 0-5° C. Added a mixture of 72 ml of 30% hydrogen peroxide and 1.0 grams of ammonium heptamolybdate tetrahydrate. Stirred the mixture for 3 hours. Quenched the reaction mixture with chilled water and separated the organic layer and extracted the reaction mixture with methylene chloride twice. Washed the organic phase with 10% sodium sulfite solution and 5% sodium bicarbonate solution followed by washed with water. Separated the organic phase and distilled the solvent at below 60° C. under reduced pressure. The title compound is isolated using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 24 grams. M.R: 145-154° C.
Example-4 Preparation of Sulfone Compound of formula-28a
A solution of 117 grams of sulfide compound of formula-20a prepared as per the example 1 and 585 ml of methylene chloride, is cooled to 0-5° C. Added a mixture of 240.6 ml of 30% hydrogen peroxide and 2.34 grams of ammonium heptamolybdate tetra hydrate. Stirred the mixture for 5 hours. Quenched the reaction mixture with chilled water and separated the organic layer and extracted the reaction mixture with methylene chloride twice. Washed the organic phase with 10% sodium sulfite solution and 5% sodium bicarbonate solution followed by washed with water. Separated the organic phase and distilled the solvent at below 60° C. under reduced pressure. The title compound is isolated using hexanes and heptane mix as a solvent medium. Dried the compound at 60-65° C. for 3 hours.
Yield: 122 grams. M.R: 105-135° C.
Example-5 Preparation of sulfone compound of Formula-13a
A solution of 120 grams of sulfone compound of formula-28a prepared as per the example 4 and 600 ml of acetone at 30-35° C. Added 31.24 grams of potassium carbonate to the above solution then added 21.39 ml of dimethylsulfate to the above reaction mixture and stirred for 4 hours at 30-35° C. Quenched the reaction mixture with chilled water and filtered the precipitated compound. Dried the compound at 50-55° C. for 6 hours.
Yield: 110 grams. M.R: 145-155° C.
Example-6 Preparation of Sulfoxide Compound of Formula-17a
A solution of 24 grams of N-methylated sulfide compound of formula-27a prepared as per the example 2 and 240 ml of methylene chloride is cooled to 0-5° C. Added a mixture of 36 ml of hydrogen peroxide and 1.0 grams of ammonium heptamolybdate tetrahydrate. Stirred the mixture for 3 hours. Quenched the reaction mixture with chilled water and separated the organic layer and extracted the reaction mixture with methylene chloride twice. Washed the organic phase with 10% sodium sulfite solution and 5% sodium bicarbonate solution followed by washed with water. Separated the organic phase and distilled the solvent at below 60° C. under reduced pressure. The title compound is isolated using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 24 grams.
Mass spectrum: M+1 peak at 582.
Example-7 Preparation of Olefin Compound of Formula-15a
34.67 grams of potassium carbonate is added to a solution of 25 grams of sulfone compound of Formula-13a prepared as per example 3 and 125 ml of dimethyl sulfoxide at 25 to 35° C. Added 10.8 grams of Tertiary butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxane-4-yl]acetate compound of formula-14a. Stirred for 13 hours at 60 to 65° C. Quenched the reaction mixture with chilled water slowly in 30 minutes. Extracted the reaction mixture twice with ethyl acetate. Separated and washed the organic phase with saturated sodium chloride solution. Distilled the solvent completely under reduced pressure at below 70° C. hexanes added to the residue and decanted twice then dissolved the residue in toluene and isolated the title compound using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 13.5 grams. M.R: 148-155° C.
Example-8 Preparation of TBA Salt of Dihydroxy acid Compound of Formula-16a
A solution of 25 grams of olefin compound of formula 15a prepared as per example 7 and 250 ml of acetonitrile, is cooled to 23 to 28° C. Added 70.75 ml of 1.0% hydrochloric acid solution slowly to the above contents of the reaction. Stirred the reaction mixture for 4 hours at 23 to 28° C. Added 37.5 ml of 10% sodium hydroxide solution to the reaction mixture and stirred to 2 hours at 30-35° C. Adjust the pH of the reaction mixture to 3.5 to 4.5 with 10% hydrochloride. Separated the organic phase and cooled to 0-10° C. Added 8.66 grams of tertiarybutyl amine (TBA) to the contents and stirred for 1 hour at 0-5° C. Distilled the solvent completely and isolated the title compound using acetonitrile as a solvent. Dried the compound at 40-45° C. for 5 hours.
Yield: 18 grams.
Example-9 Preparation of Calcium Salt of Olefin Dihydroxy Compound of Formula-2a
A solution of 15 grams of TBA salt compound of formula-16a and 75 ml of water, is cooled to 25-30° C. Added 8.5 ml of 10% sodium hydroxide solution. Stirred for 1 hour. Adjusted the pH of the reaction mixture to 9.1 by extracting the reaction mixture thrice with tertiary butyl acetate. Added the aqueous phase of the reaction mixture to a solution of 2.55 grams of calcium chloride and 15 ml of water at 35 to 45° C. Filtered off the precipitated compound. Dried the compound at 40-45° C.
Yield: 12 grams; M.R: 145-150 (Decomposed);
Purity by HPLC is 99.50%
Example-10 Preparation of Sulfide Compound of Formula-20b
39.68 grams of 5-methoxy-2-mercapto benzimidazole compound of formula-19b is added to aqueous sodium hydroxide solution (9.61 gm sodium hydroxide in 200 ml water) at 25 to 35° C. and stirred for 15 minutes, then added a solution of 400 ml of acetone and 100 grams of [4-(4-Fluoro phenyl)-6-isopropyl-2-(N-Methyl-N-methane Sulphonyl amino pyrimidine-5yl]methyl bromide compound of formula-18a and stirred for 2 hours at 25 to 30° C. Quenched the reaction mass with chilled water filtered the obtained precipitate and dried the compound at 60-65° C. for 3 hours to get the title compound.
Yield: 110 grams. M.R: 159-163° C.
Example-11 Preparation of Sulfide Compound of Formula-20c
33.07 grams of 2-mercapto benzimidazole compound of formula-19c is added to an aqueous sodium hydroxide solution (9.61 gm of sodium hydroxide in 200 ml water) at 25 to 35° C. and stirred for 15 minutes, then added a solution of 400 ml of acetone and 100 grams of [4-(4-Fluoro phenyl)-6-isopropyl-2-(N-Methyl-N-methane Sulphonyl amino pyrimidine-5-yl]methyl bromide compound of formula-18a and stirred for 1.5 hours at 25 to 30° C. Quenched the reaction mass with chilled water filtered the obtained precipitate and dried the compound at 60-65° C. for 2 hours to get the title compound.
Yield: 106.0 grams. M.R: 188-195° C.
Example-12 Preparation of Sulfone Compound of Formula-28a
A solution of 108 grams of sulfide compound of formula-20b prepared as per the example 10, 540 ml of methylene chloride and 2.16 gr tetra butyl ammonium bromide. Added a mixture of 237.5 ml of 30% hydrogen peroxide and 2.16 grams of ammonium heptamolybdate tetrahydrate. Stirred the mixture for 4 hours. Quenched the reaction mixture with chilled water and separated the organic layer and extracted the reaction mixture with methylene chloride twice. Washed the organic phase with 10% sodium sulfite solution and 5% sodium bicarbonate solution followed by washed with water. Separated the organic phase and distilled the solvent at below 60° C. under reduced pressure. The title compound is isolated using hexanes as a solvent. Dried the compound at 60-65° C. for 3 hours.
Yield: 114 grams. M.R: 100-132° C.
Example-13 Preparation of Sulfone Compound of Formula-28b
A solution of 105 grams of sulfide compound of formula-20c prepared as per the example 11, 525 ml of methylene chloride and 2.1 grams tetrabutyl ammonium bromide. Added a mixture of 245.2 ml of 30% hydrogen peroxide and 2.1 grams of ammonium heptamolybdate tetrahydrate. Stirred the mixture for 3 hours. Quenched the reaction mixture with chilled water and separated the organic layer and extracted the reaction mixture with methylene chloride twice. Washed the organic phase with 10% sodium sulfite solution and 5% sodium bicarbonate solution followed by washed with water. Separated the organic phase and distilled the solvent at below 60° C. under reduced pressure. The title compound is isolated using hexanes as a solvent. Dried the compound at 60-65° C. for 4 hours.
Yield: 107 grams. M.R: 98-128° C.
Example-14 Preparation of N-methylated Sulfone Compound of Formula-13b
A solution of 3.0 grams of sulfone compound of formula-28a prepared as per the example 12 and 15 ml of acetone, is cooled to 0-5° C. under nitrogen atmosphere. Added 0.88 grams of potassium carbonate to the above solution then added 0.6 ml of dimethylsulfate to the above reaction mixture and stirred for 4 hours at 0-5° C. Quenched the reaction mixture with chilled water and filtered the precipitated compound. Dried the compound at 50-55° C. for 6 hours.
Yield: 1.7 grams. M.R: 122-130° C.
Example-15 Preparation of N-methylated Sulfone Compound of Formula-13c
A solution of 3.0 grams of sulfone compound of formula-28b prepared as per the example 13 and 15 ml of acetone, is cooled to 0-5° C. under nitrogen atmosphere. Added 0.93 grams of potassium carbonate to the above solution then added 0.63 ml of dimethylsulfate to the above reaction mixture and stirred for 4 hours at 0-5° C. Quenched the reaction mixture with chilled water and filtered the precipitated compound. Dried the compound at 50-55° C. for 6 hours.
Yield: 2.0 grams. M.R: 126-134° C.
Example-16 Preparation of Olefin Compound of Formula-15a
8.4 grams of cesium carbonate is added to a solution of 10 grams of sulfone compound of formula-13b prepared as per example 14 and 50 ml of dimethyl sulfoxide at 25 to 35° C. Added 4.5 grams of Tertiary butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxane-4-yl]acetate compound of formula-14a. Stirred for 3 hours at 25 to 35° C. Quenched the reaction mixture with chilled water slowly in 30 minutes. Extracted the reaction mixture twice with ethyl acetate. Separated and washed the organic phase with saturated sodium chloride solution. Distilled the solvent completely under reduced pressure at below 70° C. hexanes added to the residue and decanted twice then dissolved the residue in toluene and isolated the title compound using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 6.0 grams. M.R: 148-155° C. Purity by HPLC>96%
Example-17 Preparation of Olefin Compound of Formula-15a
8.4 grams of cesium carbonate is added to a solution of 10 grams of sulfone compound of Formula-13c prepared as per example 15 and 50 ml of dimethyl sulfoxide at 25 to 35° C. Added 4.5 grams of Tertiary butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxane-4-yl]acetate compound of formula-14a. Stirred for 3 hours at 25 to 35° C. Quenched the reaction mixture with chilled water slowly in 30 minutes. Extracted the reaction mixture twice with ethyl acetate. Separated and washed the organic phase with saturated sodium chloride solution. Distilled the solvent completely under reduced pressure at below 70° C. hexanes added to the residue and decanted twice then dissolved the residue in toluene and isolated the title compound using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 6.2 grams. M.R: 148-155° C.
Purity by HPLC>96%
Example-18 Preparation of Calcium Salt of Olefin Dihydroxy Compound of Formula-2a
A solution of 15 grams of TBA salt compound of formula-16a and 75 ml of water, is cooled to 25-30° C. Added 8.5 ml of 10% sodium hydroxide solution. Stirred for 1 hour. Adjusted the pH of the reaction mixture to 9.1 by extracting the reaction mixture thrice with tertiary butyl acetate. Added the aqueous phase of the reaction mixture to a solution of 4.3 grams of calcium acetate and 15 ml of water at 35 to 45° C. Filtered off the precipitated compound. Dried the compound at 40-45° C.
Yield: 12 grams; M.R: 145-150 (Decomposed);
Purity by HPLC is 99.50%
Example-19 Preparation of Calcium Salt of Olefin Dihydroxy Compound of Formula-2a
A solution of 12.5 grams of methyl amine salt compound of formula-16b and 65 ml of water, is cooled to 25-30° C. Added 9.5 ml of 10% sodium hydroxide solution. Stirred for 1 hour. Adjusted the pH of the reaction mixture to 9.1 by expelling the methyl amine traces. Extracted the reaction mixture thrice with tertiary butyl acetate. Added the aqueous phase of the reaction mixture to a solution of 2.79 grams of calcium acetate and 12.5 ml of water at 35 to 45° C. Filtered off the precipitated compound. Dried the compound at 40-45° C.
Yield: 9.5 grams
M.C: 4.0%
Example-20 Preparation of Calcium Salt of Olefin Dihydroxy Compound of Formula-2a
A solution of 10 grams of methyl amine salt compound of formula-16b and 50 ml of water, is cooled to 25-30° C. Added 7.8 ml of 10% sodium hydroxide solution. Stirred for 1 hour. Adjusted the pH of the reaction mixture to 9.1 by expelling the methyl amine traces. Extracted the reaction mixture thrice with tertiary butyl acetate. Added the aqueous phase of the reaction mixture to a solution of 1.701 grams of calcium chloride and 10 ml of water at 35 to 45° C. Filtered off the precipitated compound. Dried the compound at 40-45° C.
Yield: 8.7 grams.
HPLC Purity is 99%
Particle Size: D (v, 0.1) is 4.72 μm; D (v, 0.5) is 40.76 μm; D (v, 0.9) is 168.32 μm.
Example-21 Preparation of Sulfide Compound of Formula-20d
15 grams of 5-(difluoromethoxy)-2-mercapto benzimidazole compound of formula-19a is added to a 82.5 ml of 2.9% solution of sodium hydroxide at 25 to 35° C. and stirred for 15 minutes, then added a mixture of 175 ml of dimethylformamide and 25 gr of 3-(bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)quinoline compound of Formula-18b and stirred for 2 hours at 25 to 30° C. Quenched the reaction mass with chilled water filtered the obtained precipitate and dried the compound at 50-55° C. for 6 hours to get the title compound.
Yield: 32 grams. M.R: 117-125° C.
Example-22 Preparation of Sulfone Compound of Formula-28c
A solution of 25 grams of sulfide compound of formula-20d, 100 ml of methylene chloride and 1.0 grams of tetrabutyl ammonium bromide, is cooled to 0-5° C. Added a mixture of 56 ml of 30% hydrogen peroxide and 1.0 grams of ammonium heptamolybdate tetrahydrate. Stirred the mixture for 3 hours. Quenched the reaction mixture with chilled water and separated the organic layer and extracted the reaction mixture with methylene chloride twice. Washed the organic phase with 10% sodium sulfite solution and 5% sodium bicarbonate solution followed by washed with water. Separated the organic phase and distilled the solvent at below 60° C. under reduced pressure. The title compound is isolated using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 23 grams. M.R: 150-160° C.
Example-23 Preparation of N-methylated Sulfone Compound of Formula-13d
A solution of 3.0 grams of sulfone compound of formula-28c prepared as per the example 22 and 15 ml of acetone, is cooled to 0-5° C. under nitrogen atmosphere. Added 0.93 grams of potassium carbonate to the above solution then added 0.63 ml of dimethylsulfate to the above reaction mixture and stirred for 4 hours at 0-5° C. Quenched the reaction mixture with chilled water and filtered the precipitated compound. Dried the compound at 50-55° C. for 6 hours.
Yield: 3.5 grams. M.R: 158-162° C.
Example-24 Preparation of Olefin Compound of Formula-15b
5.2 grams of cesium carbonate is added to a solution of 3.5 grams of sulfone compound of Formula-13d and 20 ml of dimethyl sulfoxide at 25 to 35° C. Added 1.68 grams of Tertiary butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxane-4-yl]acetate compound of Formula-14a. Stirred for 3 hours at 25 to 35° C. Quenched the reaction mixture with chilled water slowly in 30 minutes. Extracted the reaction mixture twice with ethyl acetate. Separated and washed the organic phase with saturated sodium chloride solution. Distilled the solvent completely under reduced pressure at below 70° C. hexanes added to the residue and decanted twice then dissolved the residue in toluene and isolated the title compound using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 1.2 grams. M.R: 115-121° C.
Example-25 Preparation of Sulfide Compound of Formula-20e
6.0 grams of 5-(difluoromethoxy)-2-mercapto benzimidazole compound of formula-19c is added to a 36 ml of 2.9% solution of sodium hydroxide at 25 to 35° C. and stirred for 15 minutes, then added a mixture of 30 ml of acetone and 10 grams of 2-(bromomethyl)-3-(4-fluorophenyl)-1-isopropyl-1H-indole compound of formula-18c and stirred for 2 hours at 25 to 30° C. Quenched the reaction mass with chilled water filtered the obtained precipitate and dried the compound at 50-55° C. for 6 hours to get the title compound.
Yield: 10 grams.
Example-26 Preparation of Sulfone Compound of Formula-28d
A solution of 10 grams of sulfide compound of formula-20e, 100 ml of methylene chloride and 0.5 grams of tetrabutyl ammonium bromide, is cooled to 0-5° C. Added a mixture of 14 ml of 30% hydrogen peroxide and 1 gram of ammonium heptamolybdate tetrahydrate. Stirred the mixture for 3 hours. Quenched the reaction mixture with chilled water and separated the organic layer and extracted the reaction mixture with methylene chloride twice. Washed the organic phase with 10% sodium sulfite solution and 5% sodium bicarbonate solution followed by washed with water. Separated the organic phase and distilled the solvent at below 60° C. under reduced pressure. The title compound is isolated using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 6.0 grams.
Example-27 Preparation of N-methylated Sulfone Compound of Formula-13e
A solution of 5 grams of sulfone compound of formula-28d prepared as per the example 26 and 25 ml of acetone, is cooled to 0-5° C. under nitrogen atmosphere. Added 1.35 grams of potassium carbonate to the above solution then added 3.1 ml of dimethylsulfate to the above reaction mixture and stirred for 4 hours at 0-5° C. Quenched the reaction mixture with chilled water and filtered the precipitated compound. Dried the compound at 50-55° C. for 6 hours.
Yield: 3.0 grams.
Example-28 Preparation of Olefin Compound of Formula-15c
2.7 grams of potassium carbonate is added to a solution of 3.0 grams of sulfone compound of Formula-13e prepared as per example 27 and 10 ml of dimethyl sulfoxide at 25 to 35° C. Added 1.5 grams of Tertiary butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxane-4-yl]acetate compound of Formula-14a. Stirred for 3 hours at 25 to 35° C. Quenched the reaction mixture with chilled water slowly in 30 minutes. Extracted the reaction mixture twice with ethyl acetate. Separated and washed the organic phase with saturated sodium chloride solution. Distilled the solvent completely under reduced pressure at below 70° C. hexanes added to the residue and decanted twice then dissolved the residue in toluene and isolated the title compound using hexanes as a solvent. Dried the compound at 40-45° C. for 6 hours.
Yield: 0.6 grams
Example-29 Preparation Tertiarybutyl Amine Salt of Rosuvastatin Compound of Formula-5A
A mixture of 23.1 Kgs. compound of formula-3A and 90 liters of dimethylsulfoxide and 48 Kgs. of potassium carbonate is heated to 70-75° C. Added a solution of 15 Kgs. of aldehyde compound of formula-4 in 90 liters of dimethylsulfoxide lot wise to the above reaction mixture. Stirred the reaction mixture for 4 hours at 70-75° C. Added 225 liters of toluene to the above reaction mixture. Stirred the reaction mixture for 45 minutes at 25-30° C. Filtered the byproduct and washed the byproduct with toluene. Added 240 liters of water followed by aqueous sodium chloride solution to the above reaction mixture. Stirred the reaction mixture for 15 minutes. Separated the organic and aqueous layer. Extracted the aqueous layer with toluene. Washed the total organic layer with water. Purified the organic layer with silica gel. Distilled the solvent completely under reduced pressure at below 70° C. Cooled the reaction mixture to 25-30° C. Dissolved the residue in 90 liters of acetonitrile and stirred the reaction mixture for 15 minutes at 25-30° C. Adjusted the pH of the reaction mixture to 1.4 with aqueous hydrochloric acid solution at 23-28° C. Stirred the reaction mixture for 4 hours at 23-28° C. Heated the reaction mixture to 30-35° C. Added sodium hydroxide solution (1.5 Kgs. in 60 liters of water) to the above reaction mixture at 30-35° C. Stirred the reaction mixture for 1.5 hours at 30-35° C. Distilled the solvent completely under reduced pressure at below 60° C. Cooled the reaction mixture to 25-30° C. Diluted the above reaction mixture with water. Washed the reaction mixture with tertiary butyl acetate. Added 90 liters of acetonitrile and 30 Kgs. of sodium chloride to the reaction mixture. Cooled the reaction mixture to 0-5° C. Adjusted the pH of the reaction mixture to 4.3 with 10% hydrochloric acid solution. Stirred the reaction mixture for 15 minutes. Separated the organic and aqueous layer. Cooled the organic layer to 0-10° C. Added 3.9 liters of tertiarybutyl amine to the above reaction mixture at 0-10° C. Raised the temperature to 25-35° C. Stirred the reaction mixture for 60 minutes. Distilled the solvent completely under reduced pressure at below 50° C. Added 30 liters of acetonitrile to the above crude then distilled the solvent completely under reduced pressure at below 50° C. Added 90 liters of acetonitrile to the above reaction mixture and cooled to 25-35° C. Stirred the reaction mixture for 1.5 hours at 25-35° C. Cooled the reaction mixture to 0-10° C. and stirred for 60 minutes. Filtered the precipitated solid and washed with acetonitrile. Added 90 liters of acetonitrile and 10.5 liters of isopropyl alcohol to the above obtained solid. Heated the reaction mixture slowly to reflux temperature of 70-75° C. Stirred the reaction mixture for 30 minutes at reflux. Cooled the reaction mixture to 25-30° C. in 1.5 hours. Stirred the reaction mixture for 30 minutes at 25-30° C. Filtered the precipitated solid and washed with acetonitrile. Dried the solid at 40-45° C. for 4 hours to get the title compound.
Yield: 11.8 Kgs.
Example-30 Preparation of Rosuvastatin Calcium Compound of Formula-1A
A solution of 12.5 Kgs of rosuvastatin tertiarybutyl amine compound of Formula-5A and 63 liters of water is cooled to 25-30° C. Added aqueous sodium hydroxide solution (0.9 Kgs. in 11 liters of water) to the reaction mixture. Stirred the reaction mixture for 1 hour. Adjusted the pH of the reaction mixture to 9.1 by extracting the reaction mixture thrice with tertiary butyl acetate. Added the aqueous phase of the reaction mixture to a solution of 2.1 Kgs. of calcium acetate in 12.5 liters of water at 35 to 45° C. Filtered the precipitated compound. Dried the compound at 40-45° C.
Yield: 10.6 Kgs.
M.C: 3.1%
Example-31 Preparation Tertiarybutyl Amine Salt of Rosuvastatin compound of Formula-5A
A mixture of 23.1 Kgs. compound of formula-3A and 90 liters of dimethylsulfoxide and 48 Kgs. of potassium carbonate is heated to 70-75° C. Added a solution of 15 Kgs. of aldehyde compound of formula-4 in 90 liters of dimethylsulfoxide lot wise to the above reaction mixture. Stirred the reaction mixture for 4 hours at 70-75° C. Added 225 liters of toluene to the above reaction mixture. Stirred the reaction mixture for 45 minutes at 25-30° C. Filtered the byproduct and washed the byproduct with toluene. Added 240 liters of water followed by aqueous sodium chloride solution to the above reaction mixture. Stirred the reaction mixture for 15 minutes. Separated the organic and aqueous layer. Extracted the aqueous layer with toluene. Washed the total organic layer with water. Distilled the solvent completely under reduced pressure at below 70° C. Cooled the reaction mixture to 25-30° C. Dissolved the residue in 90 liters of acetonitrile and stirred the reaction mixture for 15 minutes at 25-30° C. Adjusted the pH of the reaction mixture to 1.4 with aqueous hydrochloric acid solution at 23-28° C. Stirred the reaction mixture for 4 hours at 23-28° C. Heated the reaction mixture to 30-35° C. Added sodium hydroxide solution (1.5 Kgs. in 60 liters of water) to the above reaction mixture at 30-35° C. Stirred the reaction mixture for 1.5 hours at 30-35° C. Distilled the solvent completely under reduced pressure at below 60° C. Cooled the reaction mixture to 25-30° C. Diluted the above reaction mixture with water. Washed the reaction mixture with tertiary butyl acetate. Added 90 liters of acetonitrile and 30 Kgs. of sodium chloride to the reaction mixture. Cooled the reaction mixture to 0-5° C. Adjusted the pH of the reaction mixture to 4.3 with 10% hydrochloric acid solution. Stirred the reaction mixture for 15 minutes. Separated the organic and aqueous layer. Cooled the organic layer to 0-10° C. Added 3.9 liters of tertiarybutyl amine to the above reaction mixture at 0-10° C. Raised the temperature to 25-35° C. Stirred the reaction mixture for 60 minutes. Distilled the solvent completely under reduced pressure at below 50° C. Added 30 liters of acetonitrile to the above crude then distilled the solvent completely under reduced pressure at below 50° C. Added 90 liters of acetonitrile to the above reaction mixture and cooled to 25-35° C. Stirred the reaction mixture for 1.5 hours at 25-35° C. Cooled the reaction mixture to 0-10° C. and stirred for 60 minutes. Filtered the precipitated solid and washed with acetonitrile. Added 90 liters of acetonitrile and 10.5 liters of isopropyl alcohol to the above obtained solid. Heated the reaction mixture slowly to reflux temperature of 70-75° C. Stirred the reaction mixture for 30 minutes at reflux. Cooled the reaction mixture to 25-30° C. in 1.5 hours. Stirred the reaction mixture for 30 minutes at 25-30° C. Filtered the precipitated solid and washed with acetonitrile. Dried the solid at 40-45° C. for 4 hours to get the title compound.
Yield: 12 Kgs.
Example-32 Preparation of Rosuvastatin Calcium Salt Compound of Formula-1A
An aqueous solution of lithium hydroxide (0.81 grams in 10 ml of water) was added to a solution of 10 grams of rosuvastatin tertiarybutyl amine in 50 ml of water at 25-35° C. Stirred the reaction mixture for 60 minutes at 25-35° C. Adjusted the pH of the reaction mixture to 9.1 by distillation at below 40° C. Added 10 ml of water to the above reaction mixture. Filtered the reaction mixture through filter paper and washed with water. Added aqueous solution of the reaction mixture to a solution of 1.82 grams of calcium acetate in 15 ml of water at 25-35° C. Stirred the reaction mixture for 45 minutes at 25-35° C. Filtered the solid and washed with water. Dried the solid at 50-60° C. to get the title compound.
Yield: 7 grams
Example-33 Preparation of Rosuvastatin Calcium Salt Compound of Formula-1A
An aqueous solution of potassium hydroxide (1.09 grams in 10 ml of water) was added to a solution of 10 grams of rosuvastatin tertiarybutyl amine in 50 ml of water at 25-35° C. Stirred the reaction mixture for 60 minutes at 25-35° C. Adjusted the pH of the reaction mixture to 9.1 by distillation at below 40° C. Added 10 ml of water to the above reaction mixture. Filtered the reaction mixture through filter paper and washed with water. Added aqueous solution of the reaction mixture to a solution of 1.82 grams of calcium acetate in 15 ml of water at 25-35° C. Stirred the reaction mixture for 45 minutes at 25-35° C. Filtered the solid and washed with water. Dried the solid at 50-60° C. to get the title compound.
Yield: 7 grams
Example-34 Preparation of Diisopropyl Amide Compound of Rosuvastatin of Formula-10A
A mixture of 0.77 grams of compound of Formula-3A, 10 ml of dimethylsulfoxide and 1.6 grams of potassium carbonate is heated to 70-75° C. Added a solution of aldehyde compound of Formula-4 in 10 ml of dimethylsulfoxide to the above reaction mixture. Stirred the reaction mixture for 8 hours at 70-75° C. Added 25 ml of toluene to the above reaction mixture at 25-30° C. Filtered the byproduct and washed with toluene. Added 80 ml of water to the filtrate. Added 10 ml saturated sodium chloride solution to the above mixture. Stirred the reaction mixture for 10 minutes. Separated the organic and aqueous layer. Extracted the aqueous layer with toluene. Washed the total organic layer with water. Added 100 gram of silica gel to the above organic layer. Stirred the reaction mixture 20 minutes at 25-35° C. Filtered the silica gel and washed with toluene. Added 100 gram of silica gel to the filtrate and stirred for 20 minutes at 25-35° C. Filtered off the silica gel and washed with toluene. Distilled the solvent completely under reduced pressure at below 70° C. Dissolved the residue in 30 ml of acetonitrile. Added 5.0 ml of trifluoroacetic acid slowly to the above reaction mixture at 0-10° C. Stirred the reaction mixture for 20 hours at 0-10° C. Raised the temperature of the reaction mixture to 30-35° C. Concentrated the reaction mixture. Added 6.0 grams of diisopropyl amine to the reaction mass. Heated the reaction mixture to reflux. Stirred the reaction mixture for 12 hours at reflux temperature. Concentrated the reaction mixture to get the title compound as residue.
Example-35 Preparation Tertiarybutyl Amine Salt of Rosuvastatin Compound of Formula-5A
Added aqueous sodium hydroxide solution to a mixture of 60 gram of diisopropyl compound of formula-10A in 250 ml of acetonitrile. Stirred the reaction mixture for 1.5 hours at 30-35° C. Distilled the solvent completely under reduced pressure at below 60° C. Added 200 ml of D.M water to the above reaction mixture and stirred for 15 minutes. Washed the above reaction mixture with tertiary butyl acetate. Added 300 ml of acetonitrile and 100 grams of sodium chloride to the reaction mixture at 25-30° C. Cooled the reaction mixture to 1-10° C. Adjusted the pH of the reaction mixture to 4.3 with aqueous hydrochloric acid. Stirred the reaction mixture for 10 minutes. Separated the organic and aqueous layer. Cooled the organic layer to 0-10° C. Added 13 ml of tertiary butyl acetate to the above reaction mixture at 0-10° C. Raised the temperature to 25-35° C. Stirred the reaction mixture for 60 minutes at 25-35° C. Distilled the solvent completely under reduced pressure at below 50° C. Added 300 ml of acetonitrile at below 50° C. Distilled the solvent completely under reduced pressure. Added 100 ml of acetonitrile to the above residue. Stirred the reaction mixture for 1.5 hours at 25-35° C. Cooled the reaction mixture to 0-10° C. Stirred the reaction mixture for 60 minutes at 0-10° C. Filtered the solid and washed the solid with acetonitrile. Added a mixture of 300 ml of acetonitrile and 35 ml isopropyl alcohol to the above obtained wet solid. Heated the reaction mixture to 70-75° C. Stirred the reaction mixture for 30 minutes at 70-75° C. Cooled the reaction mixture to 25-30° C. in 1.5 hours. Stirred the reaction mixture for 30 minutes at 25-30° C. Filtered the solid and washed the solid with acetonitrile. Dried the solid to get the title compound.
Yield: 40 grams
Example-36 Preparation of Tertiarybutyl Amine Salt of Rosuvastatin Compound of Formula-5A
Added 35 grams of potassium carbonate to a solution of 25 grams of sulfone compound of Formula-3A, 25 ml of dimethyl sulfoxide at 25 to 35° C. Added 11 grams of 2-((4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl)-N,N-diisopropylacetamide compound of formula-7A to the above reaction mixture. Stirred the reaction mixture for 13 hours at 60 to 65° C. Quenched the reaction mixture with chilled water slowly in 30 minutes. Extracted the reaction mixture twice with ethyl acetate. Separated and washed the organic phase with saturated sodium chloride solution. Distilled the solvent completely under reduced pressure at below 70° C. Dissolved the residue in 135 ml of acetonitrile, is cooled to 23 to 28° C. Added 38.2 ml of 1.0% hydrochloric acid solution slowly to the above contents of the reaction. Stirred the reaction mixture for 4 hours at 23 to 28° C. Added 21 ml of 10% sodium hydroxide solution to the reaction mixture and stirred to 2 hours at 35-40° C. Adjust the pH of the reaction mixture to 3.5 to 4.5 with 10% hydrochloride. Separated the organic phase and cooled to 0-10° C. Added 4.75 grams of Tertiarybutyl amine to the contents and stirred for 1 hour at 0-5° C. Distilled the solvent completely and isolated the title compound using acetonitrile as a solvent. Dried the compound to get the title compound.
Yield: 43 grams
Example-37 Preparation of Rosuvastatin Calcium Compound of Formula-1A
A solution of 15 grams of Rosuvastatin tertiarybutyl amine salt compound of formula-5A and 75 ml of water is cooled to 25-30° C. Added 8.5 ml of 10% sodium hydroxide solution. Stirred for 1 hour. Adjusted the pH of the reaction mixture to 9.1 by extracting the reaction mixture thrice with tertiary butyl acetate. Added the aqueous phase of the reaction mixture to a solution of 2.55 grams of calcium chloride and 15 ml of water at 35 to 45° C. Filtered off the precipitated compound. Dried the compound at 40-45° C.
Yield: 12 grams
M.C: 3.5%
Example-38 Preparation of Tertiarybutyl Amine Salt of Rosuvastatin Compound of Formula-5A
A mixture of 77 grams of sulfone compound of formula-3A, 300 ml of dimethyl sulfoxide and 160 grams of potassium carbonate is heated to 70-75° C. Added a solution of 50 grams of aldehyde compound of formula-4 in 300 ml of dimethyl sulfoxide. Stirred the reaction mixture for 8 hours at 70-75° C. Added 750 ml of toluene to the above reaction mixture. Stirred the reaction mixture for 45 minutes at 25-30° C. Filtered the byproduct and washed with toluene. Added 800 ml of water to the filtrate followed by 100 ml of saturated sodium chloride solution. Stirred the reaction mixture for 10 minutes. Separated the organic and aqueous layers. Extracted the aqueous layer with toluene. Washed the total organic layer with water. Added 100 grams of silica gel to the organic layer. Stirred the reaction mixture for 20 minutes at 25-35° C. Filtered the silica gel and washed with toluene. Added 100 grams of silica gel to the filtrate. Stirred for 20 minutes at 25-35° C. Filtered the silica gel and washed with toluene. Distilled the solvent completely under reduced pressure at below 70° C. Added 500 ml of acetonitrile to the obtained crude. Added 50 ml of trifluoroacetic acid to the above reaction mixture at 0-10° C. Stirred the reaction mixture for 8 hours at 0-10° C. Raised the temperature to 30-35° C. Added aqueous sodium hydroxide solution (5 grams in 50 ml of water) to the reaction mixture. Stirred the reaction mixture for 1.5 hours at 25-30° C. Distilled the solvent completely under reduced pressure at below 50° C. Added 200 ml of water to the reaction mixture. Washed the reaction mixture with tertiary butyl acetate. Added 500 ml of acetonitrile to the above reaction mixture. Added 100 grams of sodium chloride to the above reaction mixture. Adjusted the pH of the reaction mixture to 4.8 with aqueous hydrochloric acid. Stirred the reaction mixture for 10 minutes. Separated the organic and aqueous layer. Cooled the organic layer to 0-10° C. Added 13 ml of tertiarybutyl amine to the organic layer at 0-10° C. Raised the reaction mixture temperature to 25-35° C. and stirred for 60 minutes. Distilled the solvent completely under reduced pressure at below 50° C. Added 100 ml of acetonitrile to the reaction mixture and distilled the solvent completely under reduced pressure. Added 300 ml of acetonitrile to the reaction mixture. Cooled the reaction mixture to 25-35° C. Stirred the reaction mixture for 1.5 hours at 25-35° C. Cooled the reaction mixture to 0-10° C. and stirred for 60 minutes at 0-10° C. Filtered the solid and washed the solid with acetonitrile. Added 300 ml of acetonitrile and 35 ml of isopropyl alcohol to the wet solid. Heated the reaction mixture to reflux at 70-75° C. Stirred the reaction mixture at reflux for 30 minutes. Cooled the reaction mixture to 25-30° C. in 1.5 hours. Stirred the reaction mixture for 30 minutes at 25-30° C. Filtered the solid and washed with acetonitrile. Dried the solid at 30-35° C. for 2 hours followed by 40-45° C. for another 4 hours to get the title compound.
Yield: 39 grams
Example-39 Preparation of Rosuvastatin Calcium Compound of Formula-1A
Added aqueous solution of sodium hydroxide (9 grams in 110 ml of water) to the solution of 125 grams of rosuvastatin tertiarybutyl amine salt compound of formula-5A in 630 ml of water at 20-30° C. Stirred the reaction mixture for 1.5 hours at 20-30° C. Extracted the reaction mixture twice with tertiary butyl acetate. Adjusted the pH of the reaction mixture to 9.1 by evaporating the aqueous reaction mixture with nitrogen under reduced pressure at below 40° C. Filtered the reaction mixture through micron filter and washed with water. The particle freed reaction mixture added to an aqueous solution of calcium acetate (21.4 grams in 125 ml of water) in 45 minutes at 25-30° C. Stirred the reaction mixture for 45 minutes at 25-30° C. Filtered the solid and washed with water at 25-30° C. Dried the solid at 25-35° C. for 6 hours followed by 40-45° C. for 5 hours to get the title compound.
Yield: 105 grams
Particle Size: D (v, 0.1) is 4.9 μm; D(v, 0.5) is 45.86 μm; D(v, 0.9) is 180.59 μm.
Particle Size after micronization: D (v, 0.1) is 2.46 μm; D(v, 0.5) is 12.85 μm; D(v, 0.9) is 46.43 μm.
Example-40 Preparation of Tertiarybutyl Amine Salt of Pitavastatin Compound of Formula-5C
A mixture of 50 grams of 2-cyclopropyl-4-(4-fluorophenyl)-3-methylquinoline compound of formula-3C, 195 ml of dimethyl sulfoxide and 104 grams of potassium carbonate is heated to 70-75° C. Added a solution of 32 grams of aldehyde compound of formula-4 in 195 ml of dimethyl sulfoxide. Stirred the reaction mixture for 8 hours at 70-75° C. Added 487 ml of toluene to the above reaction mixture. Stirred the reaction mixture for 45 minutes at 25-30° C. Filtered the byproduct and washed with toluene. Added 520 ml of water to the filtrate followed by 65 ml of saturated sodium chloride solution. Stirred the reaction mixture for 10 minutes. Separated the organic and aqueous layers. Extracted the aqueous layer with toluene. Washed the total organic layer with water. Added 65 grams of silica gel to the organic layer. Stirred the reaction mixture for 20 minutes at 25-35° C. Filtered the silica gel and washed with toluene. Added 65 grams of silica gel to the filtrate. Stirred for 20 minutes at 25-35° C. Filtered the silica gel and washed with toluene. Distilled the solvent completely under reduced pressure at below 70° C. Added 325 ml of acetonitrile to the obtained crude. Added 32.5 ml of trifluoroacetic acid to the above reaction mixture at 0-10° C. Stirred the reaction mixture for 8 hours at 0-10° C. Raised the temperature to 30-35° C. Added aqueous sodium hydroxide solution (3.25 grams in 33 ml of water) to the reaction mixture. Stirred the reaction mixture for 1.5 hours at 25-30° C. Distilled the solvent completely under reduced pressure at below 50° C. Added 130 ml of water to the reaction mixture. Washed the reaction mixture with tertiary butyl acetate. Added 325 ml of acetonitrile to the above reaction mixture. Added 64 grams of sodium chloride to the above reaction mixture. Adjusted the pH of the reaction mixture to 4.9 with aqueous hydrochloric acid. Stirred the reaction mixture for 10 minutes. Separated the organic and aqueous layer. Cooled the organic layer to 0-10° C. Added 8 ml of tertiarybutyl amine to the organic layer at 0-10° C. Raised the reaction mixture temperature to 25-35° C. and stirred for 60 minutes. Distilled the solvent completely under reduced pressure at below 50° C. Added 65 ml of acetonitrile to the reaction mixture and distilled the solvent completely under reduced pressure. Added 195 ml of acetonitrile to the reaction mixture. Cooled the reaction mixture to 25-35° C. Stirred the reaction mixture for 1.5 hours at 25-35° C. Cooled the reaction mixture to 0-10° C. and stirred for 60 minutes at 0-10° C. Filtered the solid and washed the solid with acetonitrile. Added 195 ml of acetonitrile and 23 ml of isopropyl alcohol to the wet solid. Heated the reaction mixture to reflux at 70-75° C. Stirred the reaction mixture at reflux for 30 minutes. Cooled the reaction mixture to 25-30° C. in 1.5 hours. Stirred the reaction mixture for 30 minutes at 25-30° C. Filtered the solid and washed with acetonitrile. Dried the solid at 30-35° C. for 2 hours followed by 40-45° C. for another 4 hours to get the title compound.
Yield: 25 grams
Example-41 Preparation of Pitavastatin Calcium Compound of Formula-1C
Added a aqueous solution of sodium hydroxide (5.4 grams in 66 ml of water) to the solution of 75 grams of pitavastatin tertiarybutyl amine salt compound of Formula-5C in 370 ml of water at 20-30° C. Stirred the reaction mixture for 1.5 hours at 20-30° C. Extracted the reaction mixture twice with tertiary butyl acetate. Adjusted the pH of the reaction mixture to 9.2 by evaporating the aqueous reaction mixture with nitrogen under reduced pressure at below 40° C. Filtered the reaction mixture through micron filter and washed with water. The particle freed reaction mixture added to an aqueous solution of calcium acetate (13 grams in 75 ml of water) in 45 minutes at 25-30° C. Stirred the reaction mixture for 45 minutes at 25-30° C. Filtered the solid and washed with water at 25-30° C. Dried the solid at 25-35° C. for 6 hours followed by 40-45° C. for 5 hours to get the title compound.
Yield: 60 grams
Example-42 Preparation of Rosuvastatin Calcium Compound of Formula-1A
Added a aqueous solution of sodium hydroxide (9 grams in 110 ml of water) to the solution of 125 grams of rosuvastatin tertiarybutyl amine salt compound of formula-5A in 630 ml of water at 20-30° C. Stirred the reaction mixture for 1.5 hours at 20-30° C. Extracted the reaction mixture twice with tertiary butyl acetate. Adjusted the pH of the reaction mixture to 9.1 by evaporating the aqueous reaction mixture with nitrogen under reduced pressure at below 40° C. Filtered the reaction mixture through micron filter and washed with water. Distilled the filtrate to dryness under reduced pressure at below 30° C. to get the sodium salt of Rosuvastatin. Adding the aqueous solution of obtained sodium salt to an aqueous solution of calcium acetate (21.4 grams in 125 ml of water) in 45 minutes at 25-30° C. Stirred the reaction mixture for 45 minutes at 25-30° C. Filtered the solid and washed with water at 25-30° C. Dried the solid at 25-35° C. for 6 hours followed by 40-45° C. for 5 hours to get the title compound.
Yield: 101 grams; M.C: 3.2%
Particle Size: D (v, 0.1) is 4.78 μm; D(v, 0.5) is 42.32 μm; D(v, 0.9) is 175.32 μm.
Particle Size after micronization: D (v, 0.1) is 2.53 μm; D(v, 0.5) is 10.54 μm; D(v, 0.9) is 34.14 μm.

Claims (10)

We claim:
1. A method for the preparation of a compound of Formula-1,
Figure US08455640-20130604-C00125
wherein R is
Figure US08455640-20130604-C00126
M is Ca+2,
the method comprising:
a) reacting a compound represented by the following structural formula
Figure US08455640-20130604-C00127
wherein R is defined as above and R2 is
Figure US08455640-20130604-C00128
wherein:
R5 is H, alkyl, alkoxy, haloalkyl, monohaloalkyloxy, or dihaloalkyloxy; and
X is N-alkyl;
with a compound of Formula-4
Figure US08455640-20130604-C00129
in the presence of an alkali or alkaline earth metal base in a polar aprotic solvent to give a condensed product, which is reacted in-situ with trifluoroacetic acid in a second solvent then hydrolyzed under basic conditions in aqueous acetonitrile then reacted with an organic amine base in a third solvent to give a compound which is purified in a fourth solvent and, optionally, dried to give a compound of Formula-5,
Figure US08455640-20130604-C00130
wherein R is defined as above and organic amine is selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine;
b) treating the compound Formula-5 with an alkali base to obtain a reaction mixture containing a compound of Formula-6:
Figure US08455640-20130604-C00131
wherein R is defined as above and M is Na+, K+ or Li+,
and adjusting the pH of the reaction mixture to 8.0 to 9.2 by washing the reaction mixture with tertiary butyl acetate or by directly distilling the reaction mixture;
c) optionally, isolating from the reaction mixture the compound of Formula-6; and
d) adding the aqueous phase of the reaction mixture from step (b) or an aqueous solution of the isolated compound of Formula-6 from step (c) to a solution of calcium chloride or calcium acetate in a solvent to give the compound of Formula-1.
2. A method for the preparation of a compound of Formula-1,
Figure US08455640-20130604-C00132
wherein R is
Figure US08455640-20130604-C00133
M is Ca+2,
the method comprising:
a) reacting a compound represented by the following structural formula
Figure US08455640-20130604-C00134
wherein R is defined as above and R2 is
Figure US08455640-20130604-C00135
wherein:
R5 is H, alkyl, alkoxy, haloalkyl, monohaloalkyloxy, or dihaloalkyloxy; and
X is N-alkyl;
with a compound of Formula-7
Figure US08455640-20130604-C00136
wherein R6 and R7 are C1-C10 straight- or branched-chain alkyl, cycloalkyl or cycloalkyl with one heteroatom,
in the presence of an alkali or alkaline earth metal base in a polar aprotic solvent to provide a compound of Formula-8,
Figure US08455640-20130604-C00137
wherein R, R6, and R7 are defined as above,
which is reacted in-situ with acid in a solvent to give a compound of Formula-9,
Figure US08455640-20130604-C00138
wherein R, R6, and R7 are defined as above,
which, upon treating with an alkali base forms a corresponding alkali salt then further treating with organic amine base, gives a compound of Formula-5, and, optionally, drying the compound of Formula-5,
Figure US08455640-20130604-C00139
wherein R is defined as above and organic amine is selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine;
b) treating the compound of Formula-5 with an alkali base to obtain a reaction mixture containing a compound of Formula-6:
Figure US08455640-20130604-C00140
wherein R is defined as above and M is Na+, K+ or Li+,
and adjusting the pH of the reaction mixture to 8.0 to 9.2 by washing the reaction mixture with tertiary butyl acetate or directly distilling the reaction mixture;
c) optionally, isolating from the reaction mixture the compound of Formula-6; and
d) adding the aqueous phase of the reaction mixture from step (b) or an aqueous solution of the isolated compound of Formula-6 from step (c) to a solution of calcium chloride or calcium acetate in a solvent to give the compound of Formula-1.
3. A method for the preparation of a compound of Formula-1,
Figure US08455640-20130604-C00141
wherein R is
Figure US08455640-20130604-C00142
M is Ca+2,
the method comprising:
a) reacting a compound represented by the following structural formula
Figure US08455640-20130604-C00143
wherein R is defined as above and R2 is
Figure US08455640-20130604-C00144
wherein:
R5 is H, alkyl, alkoxy, haloalkyl, monohaloalkyloxy, or dihaloalkyloxy; and
X is N-alkyl;
with a compound of Formula-4
Figure US08455640-20130604-C00145
in the presence of an alkali or alkaline earth metal base in a polar aprotic solvent to provide a condensed compound, which is reacted in-situ with trifluoroacetic acid to give a lactone compound, which is further reacted with organic amine HNR8R9 to give a compound of Formula-10,
Figure US08455640-20130604-C00146
wherein R is defined as above and R8 and R9 are C1-C10 straight- or branched-chain alkyl, cycloalkyl or cycloalkyl with one heteroatom;
b) reacting the compound of Formula-10 with an alkali base followed by an organic amine base to give a compound of Formula-5, and, optionally, drying the compound of Formula-5,
Figure US08455640-20130604-C00147
wherein R is defined as above and organic amine is selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine;
c) treating the compound of Formula-5 with an alkali base to obtain a reaction mixture containing a compound of Formula-6:
Figure US08455640-20130604-C00148
wherein R is defined as above and M is Na+, K+ or Li+,
and adjusting the pH of the reaction mixture to 8.0 to 9.2 by washing the reaction mixture with tertiary butyl acetate or directly distilling the reaction mixture;
d) optionally, isolating from the reaction mixture the compound of Formula-6; and
e) adding the aqueous phase of the reaction mixture from step (c) or an aqueous solution of the isolated compound of Formula-6 from step (d) to a solution of calcium chloride or calcium acetate in a solvent to give the compound of Formula-1.
4. A method for the preparation of a compound of Formula-1,
Figure US08455640-20130604-C00149
wherein R is
Figure US08455640-20130604-C00150
M is Ca+2,
the method comprising:
a) reacting a compound represented by the following structural formula
Figure US08455640-20130604-C00151
wherein R is defined as above and R2 is
Figure US08455640-20130604-C00152
wherein:
R5 is H, alkyl, alkoxy, haloalkyl, monohaloalkyloxy, or dihaloalkyloxy; and
X is N-alkyl;
with a compound of Formula-4
Figure US08455640-20130604-C00153
the presence of an alkali or alkaline earth metal base in a polar aprotic solvent to provide a compound of Formula-11,
Figure US08455640-20130604-C00154
wherein R is defined as above,
which is reacted in-situ with acid in a solvent to give a compound of Formula-12,
Figure US08455640-20130604-C00155
wherein R is defined as above,
which, upon treating with an alkali base then further treating with an organic amine base, gives a compound of Formula-5, and, optionally, drying the compound of Formula-5,
Figure US08455640-20130604-C00156
wherein R is defined as above and organic amine is selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine;
b) treating the compound of Formula-5 with an alkali base to obtain a reaction mixture containing a compound of Formula-6:
Figure US08455640-20130604-C00157
wherein R is defined as above and M is Na+, K+ or Li+,
and adjusting the pH of the reaction mixture to 8.0 to 9.2 by washing the reaction mixture with tertiary butyl acetate or directly distilling the reaction mixture;
c) optionally, isolating from the reaction mixture the compound of Formula-6; and
d) adding the aqueous phase of the reaction mixture from step (b) or an aqueous solution of the isolated compound of Formula-6 from step (c) to a solution of calcium chloride or calcium acetate in a solvent to give the compound of Formula-1.
5. A process for the preparation of a compound of Formula-2,
Figure US08455640-20130604-C00158
wherein:
R1 is
Figure US08455640-20130604-C00159
‘
Figure US08455640-20130604-P00004
’ denotes single or double bond; and
M is Na+, K+, Mg+2, or Ca+2,
the method comprising;
a) reacting a compound represented by the following structural formula:
Figure US08455640-20130604-C00160
wherein R1 is defined as above and R2 is
Figure US08455640-20130604-C00161
wherein:
R5 is H, alkyl, alkoxy, haloalkyl, monohaloalkoxy, or dihaloalkoxy; and
X is N-alkyl;
with a compound of Formula-14
Figure US08455640-20130604-C00162
wherein R10 is alkyl, cycloalkyl, arylalkyl, aryl or carbonylbenzyloxy,
in the presence of an alkali or alkaline earth metal base in a polar aprotic solvent to provide a compound of Formula-15,
Figure US08455640-20130604-C00163
wherein R1 and R10 are defined as above;
b) subjecting the compound of Formula-15 to acidic conditions to form a diol, hydrolyzing the diol under basic conditions to form a hydrolyzed product, then treating the hydrolyzed product with an organic amine base to give a compound of Formula-16,
Figure US08455640-20130604-C00164
wherein R1 is defined as above and the organic amine is selected from methyl amine, ethyl amine, tertiarybutyl amine, diisopropyl amine, dicyclohexyl amine, isobutyl amine, n-butylamine, (+/−) 2-butyl amine, phenyl ethyl amine, morpholine and pyrrolidine;
c) optionally, treating the compound of Formula-16 with an acid to give a compound of Formula-21,
Figure US08455640-20130604-C00165
wherein R1 is defined as above, and hydrogenating the compound of Formula-21 to provide a compound of Formula-22,
Figure US08455640-20130604-C00166
wherein R1 is defined as above; and
d) treating the compound of Formula-16 with an alkali base then an alkali or alkaline earth metal salt in a solvent or treating the compound of Formula-22 with an alkali or alkaline earth metal salt in a solvent to obtain the compound of Formula-2.
6. The method of claim 1, wherein:
in step a), the alkali or alkaline earth metal base is sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, or cesium carbonate; the polar aprotic solvent is dimethylformamide, dimethylsulfoxide, dimethylacetamide, or toluene, or a mixture thereof; the solvent is acetonitrile; the third solvent is methanol, ethanol, isopropyl alcohol, or acetonitrile, or a mixture thereof; or the organic amine is tertiarybutyl amine or n-butylamine;
in step b), the alkali base is sodium hydroxide, potassium hydroxide, or lithium hydroxide; or
in step d), the solvent is water.
7. The method of claim 2, wherein:
in step a), the alkali or alkaline earth metal base is sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, or cesium carbonate; the polar aprotic solvent is dimethylformamide, dimethylsulfoxide, or dimethylacetamide, or a mixture thereof; the acid is hydrochloric acid, acetic acid, or sulfuric acid; the alkali base is sodium hydroxide, potassium hydroxide or lithium hydroxide; or the organic amine is tertiarybutyl amine or n-butylamine;
in step b), the alkali base is sodium hydroxide, potassium hydroxide, or lithium hydroxide; or
in step d), the solvent is water.
8. The method of claim 3, wherein:
in step a), the alkali or alkaline earth metal base is sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, or cesium carbonate; or the polar aprotic solvent is dimethylformamide, dimethylsulfoxide, or dimethylacetamide, or a mixture thereof;
in step b), the alkali base is sodium hydroxide, potassium hydroxide, or lithium hydroxide; or the organic amine is tertiarybutyl amine or n-butylamine;
in step c), the alkali base is sodium hydroxide, potassium hydroxide, or lithium hydroxide; or
in step e), the solvent is water.
9. The method of claim 4, wherein:
in step a), the alkali or alkaline earth metal base is sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, or cesium carbonate; the polar aprotic solvent is dimethylformamide, dimethylsulfoxide, or dimethylacetamide, or a mixture thereof; the acid is hydrochloric acid, acetic acid, or sulfuric acid; the alkali base is sodium hydroxide, potassium hydroxide or lithium hydroxide; or the organic amine is tertiarybutyl amine or n-butylamine;
in step b), the alkali base is sodium hydroxide, potassium hydroxide or lithium hydroxide; or
in step d), the solvent is water.
10. The process of claim 5, wherein:
in step a), the alkali or alkaline earth metal base is sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, lithium carbonate, or cesium carbonate; or the polar aprotic solvent is dimethylformamide, dimethylsulfoxide, or dimethylacetamide, or a mixture thereof;
in step b), the compound of Formula-15 is subjected to hydrochloric acid, acetic acid, or sulfuric acid; the diol is hydrolyzed with sodium hydroxide; or the organic amine is tertiarybutyl amine or n-butylamine; or
in step e), the alkali base is sodium hydroxide; the alkali or alkaline earth metal salt is calcium chloride, calcium acetate, or sodium hydroxide; or the solvent is water.
US12/226,932 2006-05-03 2007-04-30 Process for statins and its pharmaceutically acceptable salts thereof Expired - Fee Related US8455640B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN805/CHE/2006 2006-05-03
IN805CH2006 2006-05-03
IN606/CHE/2007 2007-03-26
IN606CH2007 2007-03-26
PCT/IN2007/000172 WO2007125547A2 (en) 2006-05-03 2007-04-30 Novel process for statins and its pharmaceutically acceptable salts thereof

Publications (2)

Publication Number Publication Date
US20090275752A1 US20090275752A1 (en) 2009-11-05
US8455640B2 true US8455640B2 (en) 2013-06-04

Family

ID=38655913

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/226,932 Expired - Fee Related US8455640B2 (en) 2006-05-03 2007-04-30 Process for statins and its pharmaceutically acceptable salts thereof

Country Status (6)

Country Link
US (1) US8455640B2 (en)
EP (1) EP2024341B1 (en)
ES (1) ES2564250T3 (en)
HU (1) HUE027872T2 (en)
SI (1) SI2024341T1 (en)
WO (1) WO2007125547A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
EP2086945B1 (en) * 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US20100069635A1 (en) * 2006-11-29 2010-03-18 Dr. Reddy's Laboratories Ltd. Rosuvastatin dehydroabietylamine salt
WO2010023678A1 (en) * 2008-08-27 2010-03-04 Biocon Limited A process for preparation of rosuvastatin intermediate
EP2334667A4 (en) * 2008-09-09 2011-10-26 Biocon Ltd A process for preparation of rosuvastatin acetonide calcium
WO2010077062A2 (en) * 2008-12-29 2010-07-08 Hanmi Pharm. Co., Ltd. Preparation method of statin compound and benzothiazolyl sulfone compound used therein
SI2387566T1 (en) * 2009-01-14 2014-07-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of rosuvastatin
EA021942B1 (en) 2009-01-15 2015-10-30 Эгиш Дьёдьсердьяр Зрт. Process for the preparation of rosuvastatin salts
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd Improved process for the preparation of highly pure (3r,5s)-7-ý2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl¨-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
KR101157314B1 (en) * 2009-06-05 2012-06-15 주식회사종근당 New preparation of Rosuvastatin, the useful intermediates thereof and preparation of the same
WO2011083495A2 (en) * 2010-01-07 2011-07-14 Msn Laboratories Limited Process for the preparation of dihydroxy protected derivatives and novel intermediate compounds
US20120022102A1 (en) * 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
WO2011104725A2 (en) 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
WO2011121595A1 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. A process for the preparation of rosuvastatin calcium
AU2011243948B2 (en) 2010-04-23 2014-07-17 Sun Pharmaceutical Industries Limited Novel intermediates for the preparation of HMG-CoA reductase inhibitors
EP2383260A3 (en) * 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
ITMI20110397A1 (en) * 2011-03-14 2012-09-15 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF PYAVASTATIN AND ANALOGUES
WO2012063254A1 (en) * 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
HU230987B1 (en) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Process for the preparation of pharmaceutical intermediates with high purity
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN102174039B (en) * 2011-03-10 2013-11-06 上海交通大学 Preparation method of high-optical-purity pitavastatin calcium key intermediate
CN102816114B (en) * 2011-06-09 2014-01-29 上海京新生物医药有限公司 Preparation method of HMG-CoA reductase inhibitor
CN103058925B (en) * 2011-11-02 2015-09-02 石药集团中奇制药技术（石家庄）有限公司 A kind of preparation method of Pitavastatin Calcium
JP2013103884A (en) * 2011-11-10 2013-05-30 Daito Kk Industrial production method of pitavastatin calcium salt
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
CN103508946B (en) * 2012-06-20 2016-06-29 徐州万邦金桥制药有限公司 The preparation method of Pitavastatin Calcium
CN102898367B (en) * 2012-11-15 2014-04-30 江苏阿尔法药业有限公司 Preparation method of pitavastatin calcium crude drug midbody
WO2014203045A1 (en) 2013-06-20 2014-12-24 Lupin Limited A novel, green and cost effective process for synthesis of tert-butyl (3r,5s)-6-oxo-3,5-dihydroxy-3,5-o-isopropylidene-hexanoate
WO2015037018A1 (en) * 2013-09-14 2015-03-19 Ind-Swift Laboratories Limited Process for the preparation of rosuvastatin via novel intermediates
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
CN105873496A (en) * 2014-11-17 2016-08-17 奥林巴斯株式会社 Endoscope reprocessor
KR20160126700A (en) 2015-04-24 2016-11-02 미래파인켐 주식회사 New Statin intermediate, the preparation of the same and the preparation of Rosuvastatin using the same
CN106854201B (en) * 2017-01-03 2019-12-06 浙江海洲制药有限公司 Purification method of rosuvastatin calcium intermediate
CN109574939B (en) * 2017-09-28 2022-05-27 安徽省庆云医药股份有限公司 Preparation method of rosuvastatin sodium
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
CN109053568A (en) * 2018-08-29 2018-12-21 南京卓康医药科技有限公司 A kind of high-purity Pitavastatin Calcium novel crystal forms and preparation method thereof
CN109651259B (en) * 2018-12-29 2020-05-19 浙江永太科技股份有限公司 Purification method of rosuvastatin calcium key intermediate
CN111518035A (en) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 Rosuvastatin tert-butylamine salt and preparation method thereof
CN112592336A (en) * 2021-01-28 2021-04-02 安徽美诺华药物化学有限公司 High-grade intermediate of rosuvastatin calcium and preparation method thereof

Citations (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4970313A (en) 1987-12-08 1990-11-13 Hoechst Aktiengesellschaft Optically active 3-demethylmevalonic acid derivatives, and intermediates
US5260440A (en) 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
US5273995A (en) 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
JPH0641114A (en) 1992-05-25 1994-02-15 Nissan Chem Ind Ltd New mevalonolactones and its production
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
EP0304063B1 (en) 1987-08-20 1994-11-30 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
WO1995013283A1 (en) 1993-11-08 1995-05-18 Apotex Inc. Process for producing simvastatin and analogs thereof
WO1997019917A1 (en) 1995-11-28 1997-06-05 L'oreal METHOD FOR PREPARING (+)COMPACTIN AND (+)MEVINOLIN ANALOG COMPOUNDS HAVING A β-HYDROXY-δ-LACTONE GROUPING
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
US5763675A (en) 1993-07-08 1998-06-09 Zeneca Limited Process for the preparation of 2-hydroxyarylaldehydes under reduced pressure
WO1998032751A1 (en) 1997-01-28 1998-07-30 Plus Chemicals B.V. Process for the production of semi synthetic statins via novel intermediates
US5856336A (en) 1987-08-20 1999-01-05 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
WO1999011258A1 (en) 1997-08-28 1999-03-11 Novartis Ag Lymphocyte function antigen-1 antagonists
WO1999045003A1 (en) 1998-03-05 1999-09-10 Synthon B.V. Process for producing simvastatin and/or its derivatives
WO2001060804A1 (en) 2000-02-15 2001-08-23 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US6316460B1 (en) 2000-01-26 2001-11-13 Astrazeneca Ab Pharmaceutical compositions
WO2002009697A1 (en) 2000-07-27 2002-02-07 Plus Chemicals, B.V Highly purified simvastatin compositions
WO2002092570A1 (en) 2001-05-15 2002-11-21 Ube Industries, Ltd. Process for producing (3r,5s)-7-substituted-3,5-dihydroxyhept-6-enoic acid
WO2002094804A1 (en) 2001-05-18 2002-11-28 Aurobindo Pharma Limited A process for lactonization to produce simvastatin
WO2003006439A1 (en) 2001-07-13 2003-01-23 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
WO2003016317A1 (en) 2001-08-16 2003-02-27 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
WO2003045935A1 (en) 2001-11-29 2003-06-05 Fermic S.A. De C.V. Method for alkylating the alpha carbon of the 2-methylbutyrate secondary chain of lovastatin
WO2003070717A1 (en) 2002-02-21 2003-08-28 Novartis Ag Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2003097614A2 (en) 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004014872A1 (en) 2002-08-13 2004-02-19 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
US20040049036A1 (en) 1999-02-17 2004-03-11 Astrazeneca Ab Process for the production of tert-butyl (E)-(6-[2-[4-(-flourophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)-2, 2-dimethyl[1, 3]oioxan-4yl)acetace
WO2004108691A1 (en) 2003-06-05 2004-12-16 Astrazeneca Uk Limited Improved production of rosuvastatin calcium salt
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
US6875867B2 (en) * 2001-06-06 2005-04-05 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors
US20050080134A1 (en) 2003-08-28 2005-04-14 Valerie Niddam-Hildesheim Process for preparation of rosuvastatin calcium
WO2005033083A1 (en) 2003-10-03 2005-04-14 Nissan Chemical Industries, Ltd. Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative
WO2005040134A1 (en) 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
WO2005042522A1 (en) 2003-10-24 2005-05-12 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
US20050124639A1 (en) 2003-12-04 2005-06-09 Narendra Joshi Process for the preparation of pyrimidine derivatives
EP1099694B1 (en) 1998-07-23 2005-08-17 Nissan Chemical Industries, Ltd. Process for the preparation of quinoline derivative and intermediate therefor
WO2005077916A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
US20050209259A1 (en) 2004-03-17 2005-09-22 Le Huang Novel anhydrous amorphous forms of rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium
US20060004200A1 (en) 2004-06-21 2006-01-05 Srinivasulu Gudipati Processes to produce intermediates for rosuvastatin
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
WO2006079611A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
CN1821242A (en) * 2006-02-16 2006-08-23 亚邦化工集团有限公司 Novel method for preparing dihydroxy acid HMG CoA reductase inhibitor
WO2006136407A1 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
WO2007000121A1 (en) 2005-06-29 2007-01-04 Zentiva, A.S. A method for the production of the hemi-calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2007041666A1 (en) 2005-10-04 2007-04-12 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
WO2007040940A1 (en) 2005-10-03 2007-04-12 Teva Pharmaceutical Industries Ltd. Diastereomeric purification of rosuvastatin
WO2007052309A2 (en) 2005-11-03 2007-05-10 Morepen Laboratories Limited Improved process for manufacturing statins
WO2007086082A2 (en) 2006-01-30 2007-08-02 Cadila Healthcare Limited A process for manufacturing rosuvastatin potassium and crystalline and amorphous forms thereof
WO2007100351A2 (en) 2005-09-13 2007-09-07 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for preparing simvastatin and intermediates thereof
WO2007125547A2 (en) 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
WO2007132482A2 (en) 2006-05-17 2007-11-22 Manne Satyanarayana Reddy Novel process for the preparation of pitavastatin and its pharmaceutically acceptable salts
WO2008044243A2 (en) 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US7371865B2 (en) 2002-01-31 2008-05-13 Novartis Pharmaceuticals Corporation Process for the manufacture of HMG-CoA reductase inhibitors
US20090054450A1 (en) * 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
CN101386592A (en) 2008-10-30 2009-03-18 上海交通大学 Method for preparing pitavastatin calcium raw material medicine using asymmetric hydrogenation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573675A (en) * 1896-12-22 Fumigator

Patent Citations (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5856336A (en) 1987-08-20 1999-01-05 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
EP0304063B1 (en) 1987-08-20 1994-11-30 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
US4970313A (en) 1987-12-08 1990-11-13 Hoechst Aktiengesellschaft Optically active 3-demethylmevalonic acid derivatives, and intermediates
US4977279A (en) 1987-12-08 1990-12-11 Hoechst Aktiengesellschaft Process for the preparation of optically active 3-demethylmevalonic acid derivatives, and intermediates
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
US5273995A (en) 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
US5260440A (en) 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
JPH0641114A (en) 1992-05-25 1994-02-15 Nissan Chem Ind Ltd New mevalonolactones and its production
US5763675A (en) 1993-07-08 1998-06-09 Zeneca Limited Process for the preparation of 2-hydroxyarylaldehydes under reduced pressure
WO1995013283A1 (en) 1993-11-08 1995-05-18 Apotex Inc. Process for producing simvastatin and analogs thereof
WO1997019917A1 (en) 1995-11-28 1997-06-05 L'oreal METHOD FOR PREPARING (+)COMPACTIN AND (+)MEVINOLIN ANALOG COMPOUNDS HAVING A β-HYDROXY-δ-LACTONE GROUPING
WO1998032751A1 (en) 1997-01-28 1998-07-30 Plus Chemicals B.V. Process for the production of semi synthetic statins via novel intermediates
WO1999011258A1 (en) 1997-08-28 1999-03-11 Novartis Ag Lymphocyte function antigen-1 antagonists
WO1999045003A1 (en) 1998-03-05 1999-09-10 Synthon B.V. Process for producing simvastatin and/or its derivatives
EP1099694B1 (en) 1998-07-23 2005-08-17 Nissan Chemical Industries, Ltd. Process for the preparation of quinoline derivative and intermediate therefor
US20040049036A1 (en) 1999-02-17 2004-03-11 Astrazeneca Ab Process for the production of tert-butyl (E)-(6-[2-[4-(-flourophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)-2, 2-dimethyl[1, 3]oioxan-4yl)acetace
US6844437B1 (en) 1999-02-17 2005-01-18 Astrazeneca Ab Process for the production of tert-butyl (E)-(6-[2-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsufonyl)amino]pyrimidin-5-yl]vinyl]4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate
US6316460B1 (en) 2000-01-26 2001-11-13 Astrazeneca Ab Pharmaceutical compositions
WO2001060804A1 (en) 2000-02-15 2001-08-23 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US6841554B2 (en) 2000-02-15 2005-01-11 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002009697A1 (en) 2000-07-27 2002-02-07 Plus Chemicals, B.V Highly purified simvastatin compositions
WO2002092570A1 (en) 2001-05-15 2002-11-21 Ube Industries, Ltd. Process for producing (3r,5s)-7-substituted-3,5-dihydroxyhept-6-enoic acid
WO2002094804A1 (en) 2001-05-18 2002-11-28 Aurobindo Pharma Limited A process for lactonization to produce simvastatin
US6875867B2 (en) * 2001-06-06 2005-04-05 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors
WO2003006439A1 (en) 2001-07-13 2003-01-23 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US20040176401A1 (en) 2001-07-13 2004-09-09 Akio Matsushita Preparation of aminopyrimidine compounds
WO2003016317A1 (en) 2001-08-16 2003-02-27 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
WO2003045935A1 (en) 2001-11-29 2003-06-05 Fermic S.A. De C.V. Method for alkylating the alpha carbon of the 2-methylbutyrate secondary chain of lovastatin
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
US7371865B2 (en) 2002-01-31 2008-05-13 Novartis Pharmaceuticals Corporation Process for the manufacture of HMG-CoA reductase inhibitors
WO2003070717A1 (en) 2002-02-21 2003-08-28 Novartis Ag Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
WO2003097614A2 (en) 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004014872A1 (en) 2002-08-13 2004-02-19 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
WO2004108691A1 (en) 2003-06-05 2004-12-16 Astrazeneca Uk Limited Improved production of rosuvastatin calcium salt
US20050080134A1 (en) 2003-08-28 2005-04-14 Valerie Niddam-Hildesheim Process for preparation of rosuvastatin calcium
WO2005033083A1 (en) 2003-10-03 2005-04-14 Nissan Chemical Industries, Ltd. Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative
WO2005040134A1 (en) 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
WO2005042522A1 (en) 2003-10-24 2005-05-12 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US7312329B2 (en) * 2003-12-04 2007-12-25 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US20050124639A1 (en) 2003-12-04 2005-06-09 Narendra Joshi Process for the preparation of pyrimidine derivatives
WO2005077916A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
US20050209259A1 (en) 2004-03-17 2005-09-22 Le Huang Novel anhydrous amorphous forms of rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium
US20060004200A1 (en) 2004-06-21 2006-01-05 Srinivasulu Gudipati Processes to produce intermediates for rosuvastatin
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
WO2006079611A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
WO2006136407A1 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
WO2007000121A1 (en) 2005-06-29 2007-01-04 Zentiva, A.S. A method for the production of the hemi-calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2007100351A2 (en) 2005-09-13 2007-09-07 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for preparing simvastatin and intermediates thereof
WO2007040940A1 (en) 2005-10-03 2007-04-12 Teva Pharmaceutical Industries Ltd. Diastereomeric purification of rosuvastatin
WO2007041666A1 (en) 2005-10-04 2007-04-12 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
WO2007052309A2 (en) 2005-11-03 2007-05-10 Morepen Laboratories Limited Improved process for manufacturing statins
WO2007086082A2 (en) 2006-01-30 2007-08-02 Cadila Healthcare Limited A process for manufacturing rosuvastatin potassium and crystalline and amorphous forms thereof
CN1821242A (en) * 2006-02-16 2006-08-23 亚邦化工集团有限公司 Novel method for preparing dihydroxy acid HMG CoA reductase inhibitor
WO2007125547A2 (en) 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
WO2007132482A2 (en) 2006-05-17 2007-11-22 Manne Satyanarayana Reddy Novel process for the preparation of pitavastatin and its pharmaceutically acceptable salts
WO2008044243A2 (en) 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US20100056783A1 (en) 2006-10-09 2010-03-04 Manne Satyanarayana Reddy Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof
US20090054450A1 (en) * 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
US20110160225A1 (en) * 2007-06-19 2011-06-30 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
CN101386592A (en) 2008-10-30 2009-03-18 上海交通大学 Method for preparing pitavastatin calcium raw material medicine using asymmetric hydrogenation

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
Author unknown, "Process for the preparation of 2, 2-dimethyl-1, 2, 3, 7, 8, 8a-hexahydro-3, 7-dimethyl-8-[2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-napthalenyl ester and intermediates thereof", IP.com Journal, vol. 6(10A), 2 (No. IPCOM000140631D) compounds of formula IV (Sep. 17, 2006).
Brousseau, M.E., et al., "Structure and mechanism of action of HMG-CoA reductase inhibitors", The British Library-"The World's Knowledge", pp. 19-34, ed. by Gerd Schmitz and Michael Torzewski, Birkhauser (2002).
Cai, Zheng-yan et al., "Synthesis of Pitavastatin Calcium", Chinese Journal of Pharmaceuticals, 38(3): 177-182 (2007).
CN 1821242--MachineTransaltion From Espacenet, Aug. 23, 2006. *
Final Office Action mailed Sep. 24, 2012 for U.S. Appl. No. 12/531,386, titled: "Novel Process for the Preparation of Statins and Their Pharmaceutically Acceptable Salts Thereof".
International Preliminary Report on Patentability for International Application No. PCT/IN2010/000029, titled "Processes for Preparing Pitavastatin, Intermediates and Pharmaceutically Acceptable Salts Thereof", dated Jul. 19, 2011.
International Preliminary Report on Patentability from counterpart International Application No. PCT/IN2007/000172, dated Jun. 16, 2008.
International Preliminary Report on Patentability from counterpart International Application No. PCT/IN2007/000459, dated Aug. 4, 2010.
International Search Report for International Application No. PCT/IN2007/000459, dated Dec. 3, 2009.
International Search Report for International Application No. PCT/IN2010/000029, titled: "Processes for Preparing Pitavastatin, Intermediates and Pharmaceutically Acceptable Salts Thereof", dated Aug. 26, 2010.
International Search Report for PCT/IN2007/000172, dated Jan. 18, 2008.
Johnson, Douglas S. , "The Art of Drug Synthesis", Synthesis of Pitavastatin (Livalo®), pp. 177-179, ISBN: 15978-0-471-75215-8 (2007).
Miyachi, N., et al., "A Novel Synthetic Method of HMG-CoA Reductase Inhibitor NK-104 Via a Hydroboration-Cross Coupling Sequence", Tetrahedron Letters, 34(51):8267-8270 (1993).
Non-Final Office Action mailed Apr. 24, 2012 for U.S. Appl. No. 12/531,386, titled: "Novel Process for the Preparation of Statins and Their Pharmaceutically Acceptable Salts Thereof".
Patel, D.S., et al., "Process for preparation of 2,2-dimethylbutyric acid 8-ester of [1,2,6,7,8,8a(R)-hexahydro-2(S) ,6(R)-dimethyl-1(S)-naphthylethyl] tetrahydro-4-hydroxy-2H-pyran-2-one from broth containing [1,2,6,7,8,8a(R)-hexahydro-2(S) ,6(R)dimethyl-8(S)methyl-1-oxobutoxy-1-naphthyl]-3(R) ,5 (R)dihydroxyheptanoic acid", (abstract) Database CA [Online] Chemcial Abstracts Service Columbus, Ohio, US; Retrieved from STN International, Columbus, Ohio, USA. Accession No. 148:403004 RN 1015249-88-3 (2007).
Takahashi, Kyoko, et al., "Synthesis of an Artificial HMG-CoA Reductase Inhibitor NK-104 via a Hydrosilylation-Cross-Coupling Reaction", Bull. Chem. Soc. Jpn., 68:2649-2656 (1995).
Wess, G., et al., "Stereoselective Synthesis of HR 780 A New Highly Potent HMG-COA Reductase inhibitor", Tetrahedron Letters, 31(18):2545-2548 (1990).
Written Opinion of the International Preliminary Examining Authority from counterpart International Application No. PCT/IN2007/000172, dated Jan. 18, 2008.
Written Opinion of the International Searching Authority for International Application No. PCT/IN2010/000029, titled "Processes for Preparing Pitavastatin, Intermediates and Pharmaceutically Acceptable Salts Thereof", dated Aug. 26, 2010.
Written Opinion of the International Searching Authority from counterpart International Application No. PCT/IN2007/000459, dated Dec. 3, 2009.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof

Also Published As

Publication number Publication date
WO2007125547A3 (en) 2008-04-03
WO2007125547A2 (en) 2007-11-08
EP2024341A4 (en) 2013-05-01
EP2024341A2 (en) 2009-02-18
US20090275752A1 (en) 2009-11-05
EP2024341B1 (en) 2015-12-02
ES2564250T3 (en) 2016-03-21
SI2024341T1 (en) 2016-04-29
WO2007125547A9 (en) 2007-12-21
HUE027872T2 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
US8455640B2 (en) Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8987444B2 (en) Process for the preparation of amide intermediates and their use thereof
US8487105B2 (en) Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
EP1341785B1 (en) Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
US7312329B2 (en) Process for the preparation of pyrimidine derivatives
US8115004B2 (en) Process for pure montelukast sodium through pure intermediates as well as amine salts
US6867306B2 (en) Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
US8476432B2 (en) Process for the preparation of HMG-COA reductase inhibitors and intermediates thereof
US7566782B2 (en) Process for the preparation of rosuvastatin
US8404840B2 (en) Process for the preparation of endothelin receptor antagonists
SK1402004A3 (en) Process for preparing calcium salt forms of statins
US8759518B2 (en) Intermediates for the preparation of HMG CoA reductase inhibitors and processes for the preparation thereof
WO2007132482A2 (en) Novel process for the preparation of pitavastatin and its pharmaceutically acceptable salts
US8212034B2 (en) Process for preparing rosuvastatin calcium
US20060194867A1 (en) Process for the preparation of atorvastatin and intermediates
US20080009622A1 (en) Method for producing pyrimidine compound
EP1542968B1 (en) Process for preparing intermediates
US8178697B2 (en) Method for the preparation of atorvastatin and intermediates used therein
US7557238B2 (en) Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
KR20090104253A (en) Method for preparing atorvastatin, intermediate compounds used in the method and their preparation methods

Legal Events

Date Code Title Description
AS Assignment

Owner name: MSN LABORATORIES LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REDDY, MANNE SATYANARAYANA;RAJAN, SRINIVASAN THIRUMALAI;REDDY, MARAMREDDY SAHADEVA;REEL/FRAME:022365/0979

Effective date: 20090216

CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20170604